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Skeletal muscle is highly conserved among vertebrates and is essential for strength and
locomotion. This tissue becomes integrated with the skeletal system via tendons at the
myotendinous junction and with the nervous system at the neuromuscular junction. Both of
these specialized junctions are rich in extracellular matrix, a protein scaffold that occupies the
extracellular space of cells. Skeletal muscle is also highly plastic and can grow in size
(hypertrophy) or lose mass (atrophy) in response to genetic or environmental cues. Muscle
atrophy is found in individuals battling a number of neuromuscular conditions, including
muscular dystrophy.
Muscular dystrophies are a suite of incurable genetic diseases characterized by
progressive muscle wasting and weakness. Secondary dystroglycanopathies are a subset of
muscular dystrophies that result from mutations in genes that participate in Dystroglycan
glycosylation. This process is necessary in order for muscle fibers to interact with the
extracellular matrix and connect to nearby tendons and/or nerves. Patients battling secondary
dystroglycanopathies experience a wide array of symptoms and severities, even when the

molecular basis of their condition is identical. This prevents doctors and clinicians from
providing patients and their families with accurate prognoses.
Multiple roadblocks in our understanding of secondary dystroglycanopathies exist. We
previously determined that improving muscle-extracellular matrix adhesion with NAD+
supplementation is sufficient to improve muscle structure in primary dystroglycanopathy.
However, it is unknown whether this strategy is applicable to secondary dystroglycanopathies. It
is also unknown how identical molecular variants of an allele can result in phenotypic variation
among individuals with these conditions. Here, we leverage the zebrafish model system to
address these gaps. We find that NAD+ supplementation prior to muscle development improves
muscle structure in an established zebrafish model of secondary dystroglycanopathy, as well as
myotendinous junctions and neuromuscular junctions. Additionally, we show that a new
zebrafish model of secondary dystroglycanopathy exhibits phenotypic variation and plasticity
throughout the first several days of life and is not improved by NAD+ supplementation. These
studies highlight the importance of viewing secondary dystroglycanopathies as individual
conditions at both the basic and clinical levels.
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CHAPTER 1
MECHANISMS OF MUSCLE DEVELOMPENT AND DISEASE
1.1 Introduction
Many of the organisms inhabiting planet Earth possess muscle, a highly conserved tissue
that contributes to strength and locomotion. Muscle can be divided into three subtypes: cardiac,
smooth, and skeletal. In vertebrates, skeletal muscle is associated with organismal locomotion
and connects to bones via tendons. It is composed of multinucleated fibers that happen to be
some of the largest cells in our bodies. While there are multiple forms of these fibers, the two
primary types are slow-twitch muscle fibers that are responsible for endurance and fast-twitch
fibers that are associated with speed. Regardless of subtype, all skeletal muscle fibers contain
actin and myosin filaments that contribute to muscle contraction (Goody et al., 2017; Hinits and
Hughes, 2007).
Skeletal muscle relies on other tissues in the body in order to properly develop,
function, and maintain homeostasis. It becomes integrated with the skeletal system via tendons
at myotendinous junctions (MTJs) and with the nervous system at neuromuscular junctions
(NMJs). These specialized junctions help achieve proper architecture, function, and homeostasis
in skeletal muscle and are rich in extracellular matrix (ECM) (reviewed by (Goody et al., 2015)).
The ECM is a scaffold of proteins that occupies the extracellular space of cells and associates
with muscle fibers through cell-matrix adhesion complexes. Additionally, skeletal muscle is
highly plastic, meaning that it is susceptible to change based on genetic and/or environmental
input. Skeletal muscle has the ability to grow in size (hypertrophy) in response to exercise and
diet. Conversely, muscle atrophy—or wasting—can occur as a consequence of aging, cachexia, a
lack of exercise, or neuromuscular diseases. Additionally, the degree to which individuals
battling conditions that affect muscle tissue can regenerate skeletal muscle is highly variable.
1

Neuromuscular diseases are disorders that impair muscle and/or peripheral nerve
function. These conditions are prevalent in humans, and some notable examples include
congenital myasthenic syndrome, a genetic disorder of the NMJ, and muscular dystrophies, a
suite of heritable diseases associated with progressive muscle wasting and weakness. Muscular
dystrophies vary remarkably in terms of the genetic basis, age of onset, severity, and muscle
groups affected. Patients battling the same subtype of muscular dystrophy sometimes
experience drastically different symptoms and severities, even when the molecular basis of their
condition is identical.
Several roadblocks in our understanding of muscle development and disease currently
exist. The adhesion of muscle fibers to the ECM is disrupted in several forms of muscular
dystrophy. Recent work suggests that improving muscle cell-matrix adhesion his beneficial for
some of these conditions. In particular, it has been shown that increasing levels of functionally
redundant receptors can compensate in the absence of others (Goody et al., 2012; Sarathy et
al., 2017). However, it is necessary to determine the breadth at which this strategy is applicable.
Chapter 2 describes a study that addresses this in a zebrafish muscular dystrophy model that has
not been examined in this context. We determined that one previously described method of
enhancing cell-ECM adhesion improves muscle structure and function, as well as MTJ and NMJ
morphology. However, another previously described method of improving muscle structure has
a neutral effect in this model. These studies provide insight into how these specialized junctions
are affected in dystroglycanopathies and highlight the importance of viewing different types of
muscular dystrophies as individual conditions.
An additional gap in the field of muscle biology is understanding how phenotypic
variation develops among individuals carrying the same disease-causing mutation. Although the
disease-causing alleles of many forms of neuromuscular disease have been identified, the
2

unpredictable nature of some of these conditions prevents doctors and clinicians from providing
patients and their families with accurate prognoses. Chapter 3 details a study that begins to
address this gap. We engineered a zebrafish mutant by targeting a gene associated with
neuromuscular phenotypic variation via CRISPR/Cas9 mutagenesis. These fish exhibit phenotypic
variation and plasticity in muscle throughout the first several days of life. Given the idiosyncratic
nature of many neuromuscular diseases, understanding the mechanisms behind phenotypic
variation and plasticity can provide a valuable perspective on how to approach these conditions
from a clinical lens.
Throughout my graduate training in biomedical science, I learned that understanding
the basic biology of muscle homeostasis is key to creating an environment conducive to optimal
muscle health. Although it is important to consider how muscle development and homeostasis
relates to muscle disease, providing a baseline for translational research requires an
understanding of the proteins, cellular structures, and neighboring tissues that work in concert
to orchestrate muscle homeostasis. The overarching goal of my doctoral dissertation research
was to leverage the zebrafish model system to answer questions regarding cell-matrix adhesion,
neuromuscular development, and phenotypic variation in zebrafish models of muscle disease.
1.2. Structure and function of the myomatrix
Skeletal muscle is necessary for strength and locomotion and is comprised of bundles of
individual muscle fibers. Although the muscle fibers themselves are critical for homeostasis of
this organ, they must adhere to their surrounding extracellular matrix (ECM) to achieve
homeostasis. Muscle-associated ECM, or the myomatrix, is composed of a vast array of
extracellular proteins that link to structures within the muscle cell via transmembrane receptors
(Fig. 1.1A). The myomatrix provides structure and mediates bidirectional signaling between cells
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and their microenvironments (Goody et al., 2015). These attributes are important for skeletal
muscle, given its recurrent cycles of tension, contraction, and relaxation.
One specialized myomatrix component that is important for structural integrity and
signaling is the basement membrane. Basement membranes surround muscle fibers and contain
the fibrous proteins collagen-IV and laminin (Goody and Henry, 2010; Goody et al., 2015).
Laminin is composed of three types of chains that trimerize to form a complete heterotrimeric
protein (Miner and Yurchenco, 2004). The specific chains include five alpha, four beta, and three
gamma chains (Miner and Yurchenco, 2004). Different combinations of laminin heterotrimers
associated with different developmental stages and/or physiological structures. For example,
laminin-111 (lamininalpha1beta1gamma1) is primarily expressed during early muscle
development (Gullberg et al., 1999) and is later replaced by laminin-211
(lamininalpha2beta1gamma1) (Sasaki et al., 2002). Mutations in LAMA2, which encodes the
lamininalpha2 chain, are associated with merosin-deficient muscular dystrophy (MDC1A)
(Helbling-Leclerc et al., 1995). Therefore, lamininalpha2 is important for muscle homeostasis
and cell-matrix adhesion.
But how do laminins interact with muscle? Laminin interacts with two types of
transmembrane receptor complexes that connect muscle fibers to their surrounding
microenvironments. The integrin heterodimers are one of these receptor complexes. Integrin
heterodimers are composed of alpha and beta subunits and possess three distinct
conformations—active, inactive, and ligand-bound (Askari et al., 2009). Extracellularly, integrin
complexes have different ligands within the myomatrix, depending on the specific heterodimer.
For example, integrinalpha5beta1 serves as a receptor for fibronectin, whereas
integrinalpha6beta1 and integrinalpha7beta1 are receptors for laminin (Fig. 1.1A) (Goody et al.,
2015). Different integrin complexes are more prevalent at different stages of an organism’s life.
4

Figure 1.1. Structure of the myomatrix. (A) Schematic depicting adhesion complexes that link
the actin cytoskeleton of muscle fibers with basement membranes that are rich in laminin and
collagen IV. (B) The myomatrix (tan chains) surrounds the entirety of muscle tissue, bundles of
muscle fibers, and individual fibers (blue). The myotendinous junction (MTJ) and neuromuscular
junction (NMJ) link muscle fibers to tendons (gray) and nerves (black) respectively. The MTJ and
NMJ interact with muscle fibers via cell-ECM interactions. Originally from Goody et al., 2015.

Integrinalpha6beta1 is the prevailing isoform throughout early muscle development and
interacts with laminin-111 (Bajanca et al., 2006; Bronner-Fraser et al., 1992), whereas
integrinalpha7beta1 is the major laminin-binding integrin isoform in mature skeletal muscle
(Burkin and Kaufman, 1999) and interacts with laminin-211 (Holmberg and Durbeej, 2013). Loss
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of integrinalpha7 is associated with muscular dystrophy (Hayashi et al., 1998; Mayer et al.,
1997); thus, functional integrinalpha7beta1 heterodimers are essential for muscle homeostasis.
In addition to integrin receptor complexes, the dystrophin and utrophin glycoprotein
complexes (DGC and UGC) also connect the actin cytoskeleton of muscle fibers to the lamininrich basement membrane in the myomatrix (Fig. 1.1A) (Ervasti and Campbell, 1993). The DGC
contains dystrophin and is predominantly at the myotendinous junction (Ervasti and Campbell,
1993), whereas the UGC is predominantly found at the neuromuscular junction (Deconinck et
al., 1997). These complexes also contain Sarcoglycan, Sarcospan, and Dystroglycan (Michele and
Campbell, 2003). Dystroglycan (DG) is a major component of this complex and contains a
transmembrane beta subunit and an extracellular alpha subunit. This alpha subunit serves as a
receptor for laminin, perlecan, neurexin, and agrin (Michele and Campbell, 2003). The alpha
subunit of DG binds to these ECM proteins when it is glycosylated by a team of enzymes that
synthesize a glycan ligand for these proteins (detailed in Section 1.3). Given that the DGC is
necessary for muscle fibers to anchor to their extracellular environments, proper assembly of
the DGC is critical for muscle development and homeostasis.
The adhesion complexes that establish connections between muscle fibers and their
extracellular environments are functionally redundant in their role of indirectly connecting the
actin cytoskeleton of the myomatrix (Goody et al., 2012). These complexes are also critical for
linking muscle fibers to two specialized junctions—the myotendinous junction (MTJ) and the
neuromuscular junction (NMJ). These specialized junctions are rich in ECM and connect muscle
tissue to nearby tendons and nerves respectively (Goody et al., 2015) (Fig. 1.1B). The following
subsections will describe both of these regions in greater detail.

6

1.2.1. May the force be with you: ECM components of the myotendinous junction
Tendons provide an essential connection between skeletal muscle and bone that
facilitates locomotion. While tendons themselves serve a bridge between muscle and bone, the
region connecting muscle to tendons is known as the myotendinous junction (MTJ). This
specialized junction is a structural unit that consists of extracellular matrix proteins,
transmembrane receptors, and sarcolemma (the transmembrane region of muscle fibers) and
extends to the cytoskeleton. On the muscle end, the actin cytoskeleton is indirectly linked to
transmembrane proteins that interact with ECM components (Goody et al., 2017). On the
tendon side, tenocytes (tendon cells) produce collagen fibers that connect to the rest of the
ECM (Charvet et al., 2012). The MTJ is a critical structural component of muscle and is the major
site of force transmission (Charvet et al., 2012) that helps muscle contraction drive movement.
Several well-known ECM components are enriched at the MTJ. Collagen-I and tenascin
are highly concentrated on the tendon side of the junction, collagen-VI is distributed throughout
the myomatrix and provides structural stability of the sarcolemma during muscle contraction,
and laminin and collagen-IV are abundant in the muscle basement membrane (Charvet et al.,
2012; Goody et al., 2015). Throughout development, MTJ undergoes changes in composition,
especially in zebrafish. For example, fibronectin is initially present at somite boundaries, but
eventually becomes downregulated (Snow and Henry, 2009). An increase in laminin-111 at the
MTJ correlates with fibronectin downregulation (Jenkins et al., 2016; Snow et al., 2008a). A shift
from laminin-111 expression to laminin-211 expression also occurs at the MTJ in zebrafish, mice,
and humans, and laminin-211 then remains the prevailing laminin isoform at the MTJ (Charvet
et al., 2012; Goody et al., 2017).
Several additional ECM components play important roles in MTJ maintenance. CollagenVI is distributed throughout the myomatrix and provides the sarcolemma with structural
7

stability throughout muscle contraction (Telfer et al., 2010). Thrombospondins bind to
transmembrane receptors and ECM proteins to mediate cell-matrix adhesion (Charvet et al.,
2012). In Drosophila, thrombospondin is synthesized and secreted by tenocytes and binds to
muscle-specific integrin receptors (Subramanian et al., 2007). Zebrafish thrombospondin4b
(tsp4b) is critical for basement membrane assembly in tendons and for muscle attachment
during MTJ development and repair (Subramanian and Schilling, 2014). Deficiencies of ECM
components that participate in MTJ development and homeostasis are linked to aberrant
muscle development (Hall et al., 2007; Odenthal et al., 1996; Snow et al., 2008a; Subramanian
and Schilling, 2014; Telfer et al., 2010; Welser et al., 2009). Therefore, appropriate timing and
expression of these proteins is critical for MTJ development and homeostasis.
1.2.2. Communication breakdown: ECM components of the neuromuscular junction
In addition to muscle tissue and MTJs, locomotion also depends on the initiation and
regulation of muscle contraction from nerves. This occurs via the neuromuscular junction (NMJ),
a synapse that lies at the interface of motoneurons and muscle fibers. Motoneurons that
innervate muscle fibers serve as the presynaptic component and release neurotransmitters. In
vertebrates, acetylcholine is the neurotransmitter that is released, which travels to postsynaptic acetylcholine receptors (AChRs) on the surface of muscle cells (Singhal and Martin,
2011). Formation of the vertebrate NMJ relies on careful crosstalk of initial muscle and
motoneuron development. Embryonic muscle fibers are prepatterned with aneural AChRs in the
medial regions of muscle prior to innervation, the motoneuron migrates to the muscle fiber for
innervation, and synaptogenesis occurs (reviewed by (Burden et al., 2018; Tintignac et al., 2015;
Wu et al., 2010)). This process in zebrafish can be studied in the context of slow-twitch and fasttwitch muscle fibers (discussed in Section 1.5.1).
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Vertebrate NMJ development and homeostasis also relies on myomatrix components
and their receptors. Muscle fibers secrete and deposit laminin and collagen IV, the two primary
basement membrane proteins, into the synaptic cleft to form a basement membrane that
provides a barrier between the presynaptic motoneuron and the postsynaptic muscle fiber
(Singhal and Martin, 2011). The synaptic laminins that are prevalent at the NMJ are distinct from
those that are prevalent at the MTJ and include the lamininbeta2 chain. These laminins include
laminin-221 (lamininalpha2beta2gamma1), laminin-421 (lamininalpha4beta2gamma1), and
laminin-521 (lamininalpha5beta2gamma1) (Singhal and Martin, 2011). The NMJ also contains
several additional and transmembrane components that are indispensable for NMJ
development and maintenance and have been nicely reviewed (Pilgram et al., 2010; Singhal and
Martin, 2011; Tintignac et al., 2015; Wu et al., 2010). Agrin is a heparin sulfate proteoglycan
(HSPG) protein in the ECM that contributes to AChR clustering and NMJ stabilization, and neural
agrin is secreted by motoneurons and released into the basement membrane (Pilgram et al.,
2010; Singhal and Martin, 2011; Tintignac et al., 2015; Wu et al., 2010). Agrin interacts with
several receptors on the post-synaptic membrane, including alpha-DG, muscle-specific receptor
tyrosine kinase (MuSK), and the agrin co-receptor Lrp4 (Pilgram et al., 2010; Singhal and Martin,
2011; Tintignac et al., 2015; Wu et al., 2010). MuSK is necessary for AChR prepatterning and
post-synaptic differentiation, is activated by the protein Dok7, and interacts with rapsyn, leading
to MuSK signaling (Singhal and Martin, 2011; Tintignac et al., 2015). Thus, MuSK is an especially
critical contributor to NMJ development and homeostasis.
Proper coordination between muscle, motoneurons, and the signaling components that
contribute to AChR clustering and maintenance is key for NMJ assembly and function.
Autoantibodies against AChRs, MuSK, and Lrp4 are associated with autoimmune myasthenia
gravis, a progressive NMJ disease, in human populations (Pevzner et al., 2012). Studies have also
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detected NMJ abnormalities in mouse models of muscular dystrophies. These include Duchenne
Muscular Dystrophy (Pratt et al., 2015), the most well-known form of the disease, as well as
muscular dystrophies associated with compromised DG (Herbst et al., 2009; Saito et al., 2007).
Chapters 2 and 3 will discuss how the NMJ is disrupted in zebrafish models of
dystroglycanopathy.
1.3. Post-translational modification of Dystroglycan
As detailed in Section 1.2, the dystrophin glycoprotein complex (DGC) is a major
receptor complex that connects the actin cytoskeleton of muscle fibers to the laminin-rich
basement membrane in the myomatrix (Ervasti and Campbell, 1993). Major components of this
complex include dystrophin that is linked to f-actin and DG. Several muscular dystrophies are
associated with mutated components of the DGC. Mutations in Dystrophin, the intracellular
component of the DGC, are associated with Duchenne and Becker Muscular Dystrophies.
Compromised DG is associated with a broad suite of muscular dystrophies known as
dystroglycanopathies.
DG serves as a major receptor for a number of ECM proteins, including laminin. Like
many other components of the ECM and/or the neuromusculoskeletal system, a-DG is heavily
glycosylated. This process is necessary in order for interact with laminin and other ECM proteins
that are involved in cell-matrix adhesion. Multiple enzymes work in concert to synthesize this
glycan (Fig. 1.2) (reviewed by (Nickolls and Bönnemann, 2018; Taniguchi-Ikeda et al., 2016).
DOLK, GMPPB, DPM1, DPM2, and DPM3 help synthesize dolichol phosphate mannose
precursors used in o-mannosylation reactions (Carss et al., 2013; van Tol et al., 2019). When coexpressed, POMT1 and POMT2 use these precursors to add mannose (o-linked) directly
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Figure 1.2. Post-translational modification of alpha-Dystroglycan. (A) Multiple enzymes work
together to synthesize a glycan chain that links alpha-DG (light blue) to ECM proteins such as
laminin. This process is important for muscle-ECM adhesion. FKRP and GMPPB (bold font) will be
the focus of subsequent chapters in this dissertation. (B) Legend for molecules depicted in (A).
Adapted from Carss et al. (2013), Nickolls and Bönnemann (2018), Taniguchi-Ikeda et al., 2016,
and van Tol et al. (2019).

to alpha-DG (Manya et al., 2004). N-acetylglucosamine is subsequently added to mannose via
POMGNT1 and POMGNT2 (Ogawa et al., 2013; Yoshida et al., 2001), and the mannose modified
by POMGNT2 is phosphorylated by POMK (Yoshida-Moriguchi et al., 2013). B3GALNT2 adds Nacetylgalactosamine to the N-acetylglucosamine synthesized by POMGNT2 (Yoshida-Moriguchi
et al., 2013). ISPD then supplies CDP-ribitol that is used by FKRP and FKTN to produce a tandem
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ribitol 5-phosphate repeat (Gerin et al., 2016; Kanagawa et al., 2016). TMEM5 then catalyzes the
addition of xylose (Praissman et al., 2016), followed by the addition of glucuronic acid by
B4GAT1 (Willer et al., 2014). Finally, LARGE synthesizes a repeating unit of xylose and glucuronic
acid that serves as the ligand for laminin (Inamori et al., 2012). Completion of this process in the
appropriate steps is necessary for muscles to adhere to their extracellular environments and
achieve homeostasis. Failure of DG to undergo glycosylation is associated with a complex subset
of muscular dystrophies known as secondary dystroglycanopathies.
1.4. The many faces of dystroglycanopathies
The dystroglycanopathies are a group of molecularly distinct muscular dystrophies that
are associated with compromised DG function. Primary dystroglycanopathy occurs with
mutations in DG (Frost et al., 2010; Hara et al., 2011), whereas secondary dystroglycanopathies
occur due to mutations in genes that encode enzymes that participate in alpha-DG glycosylation
(Muntoni et al., 2011). A number of molecularly distinct secondary dystroglycanopathies have
been identified (Nickolls and Bönnemann, 2018); however, the clinical presentation of these
conditions is highly variable, even when the disease-causing allele is known. While some
individuals with secondary dystroglycanopathies experience limb-girdle muscular dystrophies
that are more likely to develop in adolescence, others experience severe congenital muscular
dystrophies (CMDs) (Muntoni et al., 2011). Individuals with CMDs associated with
dystroglycanopathy often experience eye and/or brain involvement in the form of Muscle-Eye
Brain Disease, Walker-Warburg Syndrome, or Cobblestone Lissencephaly (Nickolls and
Bönnemann, 2018). This level of variation prevents clinicians from providing their patients with
accurate prognoses. Poor understanding of the basic biological mechanisms of phenotypic
variation and plasticity in neuromuscular diseases are a major roadblock to understanding
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phenotypic variation in the dystroglycanopathies. Chapter 3 describes a study regarding
phenotypic variation in new zebrafish dystroglycanopathy model.
1.4.1. Fukutin-related protein (FKRP)
Fukutin-related protein (FKRP) participates in Dystroglycan (DG) glycosylation and is
associated with dystroglycanopathy in humans (Brockington et al., 2001). As previously
mentioned, FKRP is a ribitol-5 phosphate transferase that, along with Fukutin (FKTN), uses CDPribitol to form a tandem ribitol-5-phosphate (Gerin et al., 2016; Kanagawa et al., 2016) that links
N-acetylgalactosamine with xylose (Taniguchi-Ikeda et al., 2016). Failure of this linkage to form
prevents completion of alpha-DG glycosylation, reducing its affinity to bind to ECM ligands such
as laminin.
Like other dystroglycanopathies, patients harboring FKRP mutations present with
phenotypic variability. Individuals with FKRP-associated dystroglycanopathy may develop limbgirdle muscular dystrophy 2I (LGMD2I) or congenital muscular dystrophy with or without eye and
brain involvement, depending on the specific molecular variant (Stensland et al., 2011; Van
Reeuwijk et al., 2010). Although some genotype-phenotype correlation is present in patients
with FKRP mutations (Beltran-Valero de Bernabé et al., 2004; de Bernabé et al., 2003; Stensland
et al., 2011; Van Reeuwijk et al., 2010), there is sometimes phenotypic variation among
individuals with identical mutations, particularly in regard to muscle pathology, levels of
glycosylated alpha-DG, and age of onset (Stensland et al., 2011). This suggests genetic or
environmental cues could contribute to disease progression in FKRP-associated
dystroglycanopathy, as well as features other than muscle pathology and levels alpha-DG
glycosylation.
Several animal models of FKRP-associated dystroglycanopathy have been engineered.
These include Fkrp mutant mice (Ackroyd et al., 2009; Blaeser et al., 2013; Chan et al., 2010),
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fkrp morphant zebrafish, (Kawahara et al., 2010; Lin et al., 2011; Thornhill et al., 2008), and fkrp
mutant zebrafish (Serafini et al., 2018). Previous animal model have focused on levels of alphaDG glycosylation, regenerative capacity, and functional rescue. Gene therapy (Qiao et al., 2014;
Thomas et al., 2016; Tucker et al., 2018; Vannoy et al., 2017) estrogen receptor modulators (Wu
et al., 2018), and exogenous ribitol supplementation (Cataldi et al., 2018) improve muscle in
mouse models. However, the efficacy of some therapies decreases if administered later in the
mouse’s lifespan (Cataldi et al., 2018; Vannoy et al., 2017). This suggests that early intervention
is most beneficial for these conditions. However, little is known regarding how MTJs and/or
NMJs are affected in the context of FKRP deficiency. Chapter 2 describes the involvement of the
MTJ and NMJ in a zebrafish model of FKRP-associated dystroglycanopathy and implicates early
improvement of cell-matrix adhesion as a mechanism for improving muscle structure, function,
and specialized muscle junctions.
1.4.2. GDP-mannose pyrophosphyorylase B (GMPPB)
GDP-Mannose Pyrophosphorylase B (GMPPB) is an enzyme that synthesizes GDPmannose, a molecule used in several glycosylation reactions. In addition to O-mannosylation of
alpha-DG, GMPPB also participates in GPI-anchor formation, N-glycosylation, and Cmannosylation (Carss et al., 2013). Given that multiple myomatrix and NMJ proteins are also
glycosylated, it is possible that GMPPB may have additional effects on neuromuscular skeletal
system beyond alpha-DG modification. Unsurprisingly, mutations in GMPPB are associated with
dystroglycanopathies that vary drastically in their clinical presentation.
Similar to FKRP-associated dystroglycanopathy, cases of congenital muscular
dystrophies and limb-girdle muscular dystrophies (specifically Limb-Girdle Muscular Dystrophy
Type 2T (LGMD2T)) have been documented in individuals harboring GMPPB mutations (Balcin et
al., 2017; Cabrera-Serrano et al., 2015; Carss et al., 2013; Jensen et al., 2015; Montagnese et al.,
14

2017; Oestergaard et al., 2016; Raphael et al., 2014). Although molecular variants that
specifically correlate with LGMD2T or congenital muscular dystrophies have been detected
(Jensen et al., 2015), there is still a great deal of phenotypic variation in GMPPB-associated
dystroglycanopathy. Additional conditions have been observed in patients with GMPPB
mutations. Congenital myasthenic syndrome, a disease of the NMJ, has been detected in
individuals harboring mutations with the same molecular basis as LGMD2T (Belaya et al., 2015;
Luo et al., 2017; Montagnese et al., 2017; Rodríguez Cruz et al., 2016). Patients with the most
common GMPPB mutation, c.79 G>C, have ranged between 2 and 62 years old at the age of
symptomatic onset (Bharucha-Goebel et al., 2015; Montagnese et al., 2017). Cases of epilepsy
and one case of autism spectrum disorder (Astrea et al., 2018; Raphael et al., 2014) have also
been documented. These studies highlight the need to elucidate the mechanisms underlying
phenotypic variation in GMPPB-associated dystroglycanopathy in order to accurately predict the
course of the disease.
Given the poor genotype-phenotype correlation observed in these conditions, the fact
that new individuals with GMPPB mutations are often identified (Sun et al., 2019), and the lack
of genomic animal models for GMPPB-associated dystroglycanopathy, it is critical to study these
conditions outside of the clinic. In terms of model systems, GMPPB mutations are linked with
GMPPB mislocalization in cultured myoblasts, and gmppb morphant zebrafish have been
superficially characterized and exhibit hypoglycosylated alpha-DG and muscle phenotypes (Carss
et al., 2013). There are currently no published genomic models for this disorder in any model
organism. Chapter 3 documents a study where a gmppb mutant was engineered to study the
mechanisms underlying phenotypic variation in the dystroglycanopathies.
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1.5. Zebrafish as a model organism for neuromuscular development and disease
Mammalian model systems have played a key role in elucidating the molecular and
cellular biology of neuromuscular disorders. However, zebrafish (Danio rerio) offer many
advantages for studying neuromuscular development and disease. Zebrafish embryos are
externally fertilized and develop at a faster time scale than rodents. Embryonic and larval
zebrafish are also optically transparent (Gibbs et al., 2013), which allows individuals to easily
visualize their internal tissues under a fluorescence microscope, either through live imaging
transgenics or with fixed immunostaining. This attribute allows one to easily image zebrafish
muscle fibers, motoneurons, myotendinous junctions, and neuromuscular junctions throughout
the embryonic and early larval stages. Other advantages of zebrafish as a model include high
fecundity, low maintenance cost, and the ability to perform high-throughput screening in large
numbers (Gibbs et al., 2013). Herein, the processes of neuromuscular development in zebrafish
will be described, as well as current zebrafish models of muscular dystrophy and the emergence
of CRISPR/Cas9 genome editing technology.
1.5.1. Zebrafish neuromuscular development
Zebrafish muscle is organized into chevron-shaped segments called myotomes, which
are derived from somites. Like mammals, zebrafish possess slow-twitch muscle fibers that are
associated with endurance and fast-twitch muscle fibers linked to speed. Zebrafish muscle fibers
can be divided into subtypes that can be identified by specific genetic markers: superficial slowtwitch muscle fibers, slow-twitch muscle pioneers, medial fast-twitch muscle fibers, and fasttwitch fibers (Wolff et al., 2003). In contrast to mammals, zebrafish subtypes of zebrafish muscle
fibers spatially occupy distinct regions in the myotome (Goody et al., 2017). This allows for easy
identification of each fiber type, as well as how it is affected in the context of muscle
development and disease.
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But how does a zebrafish muscle segment with multiple fiber types develop? The
paraxial mesoderm is initially segmented into somites. Somites are composed of four cell
types—epithelial, mesenchymal, adaxial (slow-twitch fiber precursors), and anterior border
cells—and give rise to multiple tissues, including muscle fibers, skeleton and tendon
components, hematopoietic stem cells, and dermis of the skin (Goody et al., 2017). When
muscle begins to develop, adaxial cells located in the medial plane of muscle elongate and
subsequently migrate to the lateral surface of muscle (Devoto et al., 1996). This slow-twitch
fiber migration induces fast-twitch muscle fiber morphogenesis (Henry and Amacher, 2004).
These fast-twitch fibers elongate, and the terminal ends attach to the somite boundaries and
form myotubes (Snow et al., 2008b). Muscle cell fusion occurs to form multinucleated muscle
fibers (Powell and Wright, 2011). Finally, sarcomeres composed of thick myosin filaments and
thin actin filaments are assembled into a myofibril that is essential for muscle contraction
(Goody et al., 2017; Hinits and Hughes, 2007). All of these components must be actively
maintained in order to achieve proper muscle homeostasis.
Motoneuron development and NMJ formation in zebrafish occurs simultaneously with
muscle morphogenesis. Initially, fish muscle is innervated by the caudal (CaP), middle (MiP) and
rostral (RoP) primary motoneurons (Myers et al., 1986). Secondary motoneurons follow similar
innervation paths several hours later in development (Beattie, 2000; Fashena and Westerfield,
1999). Medial slow-twitch muscle cells secrete ECM proteins that facilitate primary motoneuron
guidance and exit from the neural tube (Guillon et al., 2016; Schweitzer et al., 2005). The medial
slow muscle fiber precursors (adaxial cells) are prepatterned with aneural AChR clusters prior to
the motoneurons reaching the choice point (Flanagan-Steet et al., 2005; Panzer et al., 2005).
When the primary motoneurons leave the choice point, the CaP extends ventrally, the MiP
extends dorsally, and the RoP remains in the middle of the myotome (Lewis and Eisen, 2003).
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Initially, synapses form on muscle fibers located in close proximity to the choice point, followed
by the medial muscle fibers, and are present in the lateral muscle by 48 hours post-fertilization
(hpf) (Panzer et al., 2005). Chapters 2 and 3 both describe studies where fast-twitch muscle fiber
innervation was quantified in zebrafish models of dystroglycanopathy.
1.5.2. Modeling muscle disease in zebrafish
Over the past two decades, zebrafish have emerged as a valuable model for studying
muscular dystrophies and other neuromuscular diseases. The optical transparency of zebrafish
embryos allows one to easily observe zebrafish muscle through transgenic zebrafish or
immunohistochemistry. Staining embryos for f-actin with fluorescently tagged phalloidin
visualizes the zebrafish muscle fibers (Fig. 1.3A-C) and can detect several muscle abnormalities
(Goody et al., 2017). Typically, zebrafish muscle fibers are organized into chevron-shaped
muscle segments. When muscle undergoes appropriate development and maintenance, these
fibers remain attached to the MTJ (Fig. 1.3A). In some cases, muscle fibers fail to be captured by
the myotome boundary and extend past the MTJ. This phenomenon is known as MTJ failure
(Fig. 1.3B) (Goody et al., 2017). At other times, muscle fibers detach from the boundaries, which
is indicative of dystrophy (Fig. 1.3C). Damage to the sarcolemma may or may not accompany
this fiber detachment (Goody et al., 2017). Therefore, both muscle and MTJ phenotypes at high
magnification can be readily quantified in zebrafish models of muscle disease. This allows
researchers to analyze muscle and MTJ abnormalities and delve into the mechanisms
contributing to these phenotypes.
Compromised zebrafish muscle can also be detected via live, non-invasive birefringence
imaging. This technique uses polarized light to detect muscle fibers that are in-tact and have
maintained their integrity (Berger et al., 2012; Gibbs et al., 2013). Such fibers retain their
birefringence and appear as well organized, bright muscle segments under polarized light
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Figure 1.3. Visualization of zebrafish muscle phenotypes. (A-C) Anterior left, dorsal top, sidemounted 48 hpf embryos stained for f-actin (phalloidin, gray) to visualize muscle fibers. (A)
Control embryo. (B) Zebrafish embryo with fibers crossing the MTJ (MTJ failure, yellow
arrowhead). (C) Zebrafish embryo with fiber detachment (dystrophy, white arrowhead). (D-E)
Anterior left, dorsal top, side-mounted 4 dpf zebrafish imaged live for birefringence. (D) Control
embryo with normal birefringence. (E) Embryo with muscle degeneration indicated by a patchy
area of birefringence (blue arrowhead).

(Fig. 1.3D). In contrast, patchy areas of birefringence are indicative of muscle damage (Fig. 1.3E)
and reduced brightness indicates muscle fiber disorganization (Gibbs et al., 2013). This
technique allows for rapid screening and quantification of muscle phenotypes (Berger et al.,
2012), particularly in regard to “mild,” “moderate,” or “severe” abnormalities in muscle
development and homeostasis.
In addition to their visual advantages, zebrafish are also a suitable model for muscle
disease at the genetic level. Many genes associated with the muscular dystrophies and other
muscle diseases are conserved in zebrafish (Gibbs et al., 2013; Goody et al., 2017), making them
an appropriate molecular model for the disease. A number of muscular dystrophies have been
modeled in the fish by impairing expression of these genes, both with genomic manipulation
and morpholino technology. Morpholinos are oligonucleotides that bind to RNA to block gene
expression. Numerous morpholinos have been developed to target the transcripts of muscular
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dystrophy genes (Carss et al., 2013; Guyon et al., 2003; Kawahara et al., 2010; Marchese et al.,
2016; Moore et al., 2008; Parsons et al., 2002; Postel et al., 2008; Roscioli et al., 2012; Stevens et
al., 2013; Thornhill et al., 2008). However, there are disadvantages to using morpholinos. In
particular, the effects of morpholinos often fade by 5 days post-fertilization (dpf) (Gibbs et al.,
2013). An alternative approach is to use zebrafish harboring genomic mutations for a gene of
interest. Several zebrafish models of muscular dystrophy, including sapje (dystrophin mutants),
candyfloss (lamininalpha2 mutants), and patchytail (dystroglycan mutants) were identified from
ENU mutagenesis screens (Bassett and Currie, 2004; Gupta et al., 2011; Hall et al., 2007).
Additionally, recent genome editing technology, including CRISPR/Cas9 mutagenesis, has yielded
opportunities for researchers to generate mutations in the zebrafish genome with high
specificity that can be used to generate new zebrafish muscular dystrophy mutants.
1.5.3. CRISPR/Cas9 mutagenesis
Three prominent genome editing techniques—zinc finger nucleases (ZFNs), transcription
activator-like effector nucleases TALENs, and CRISPR/Cas9—are commonly used in zebrafish and
allow scientists to specifically target a region of genomic DNA. Although ZFNs and TALENS have
been used extensively to generate mutant lines of interest (Rafferty and Quinn, 2018; Simone et
al., 2018), CRISPR/Cas9 mutagenesis has recently gained popularity in the zebrafish community.
CRISPR/Cas9 has garnered much attention—and some controversy—over the past several years.
This technique emerges from the adaptive immune system of bacteria and archaea. Cas9
enzyme derived from Streptococcus pyogenes or Streptococcus thermophilus accompanies
clustered regulatory interspaced short palindromic repeat (CRISPR) RNAs (crRNAs) or single
guide RNAs (sgRNAs) to target sites to cleave DNA (Cong et al., 2013; Gasiunas et al., 2012; Jinek
et al., 2012; Mali et al., 2013). Specifically, the sgRNA-Cas9 complex is guided to a DNA sequence
complementary to the sgRNA, and this sequence neighbors a protospacer adjacent motif (PAM)
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sequence (Rafferty and Quinn, 2018). Double stranded breaks are induced that can later be
repaired via two mechanisms: non-homologous end joining (NHEJ) and homology-directed
repair (HDR) (Cornet et al., 2018; Liu et al., 2019). Over the past several years, multiple
techniques for engineering CRISPR/Cas9 mutants in zebrafish have emerged and this technology
continues to evolve (reviewed by (Cornet et al., 2018; Liu et al., 2019)). Chapter 3 describes a
study where CRISPR/Cas9 mutagenesis was used to engineer a zebrafish model of GMPPBassociated dystroglycanopathy.
1.6. Concluding remarks
Skeletal muscle is important for strength and locomotion in vertebrate organisms. These
muscle fibers adhere to surrounding ECM to form cell-matrix adhesion complexes. These
connections help link muscle to nearby tendons and nerves, which contribute to its overall
function. One of these complexes, the DGC is disrupted in secondary dystroglycanopathies,
which are muscular dystrophies associated with progressive muscle wasting and weakness and
phenotypic variation. It is currently unknown whether improving muscle cell-ECM adhesion is
sufficient to improve muscle structure in secondary dystroglycanopathies. Chapter 2 describes a
study that demonstrates that one of these strategies is sufficient prior to muscle development.
It is also unknown how identical molecular variants of a GMPPB allele can result in phenotypic
variation. Chapter 3 documents how we engineered an animal model of GMPPB-associated
dystroglycanopathy that exhibits phenotypic variation and plasticity throughout the first several
days of life. Both of these studies leverage the advantages of the zebrafish model system to
answer questions regarding neuromuscular development and phenotypic variation in secondary
dystroglycanopathies.
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CHAPTER 2
NAD+ IMPROVES NEUROMUSCULAR DEVELOPMENT IN A ZEBRAFISH MODEL
OF FKRP-ASSOCIATED DYSTROGLYCANOPATHY
2.1. Introduction
Muscle is a highly conserved tissue that part of the neuromusculoskeletal system and is
essential for strength, locomotion, and health. The neuromuscular junction (NMJ) initiates
muscle contraction, whereas the myotendinous junction (MTJ) is the major site of force
transmission from muscle to the skeletal system. Muscle fibers adhere to their surrounding
extracellular matrix (ECM), the MTJ, and the NMJ; and these adhesion complexes are critical for
muscle development and homeostasis (reviewed by (Goody et al., 2015)). The muscle
extracellular matrix and adhesion complexes at MTJs and NMJs are specialized and allow the
muscle to adhere to and interact with neurons and tendons during development and
homeostasis. Thus, regulation of cell-ECM adhesion is essential for development and
homeostasis of the neuromusculoskeletal system.
The dystrophin-glycoprotein complex (DGC) is an essential component of muscle-ECM
adhesion. The DGC is a multi-protein complex that indirectly links the actin cytoskeleton of
muscle fibers to the laminin-rich basement membrane in the ECM (Ervasti and Campbell, 1993).
The DGC is thought to provide mechanical stabilization during muscle contraction (Ervasti and
Campbell, 1993; Rybakova et al., 2000) in addition to its role as a signaling complex (Constantin,
2014). Different variants of the DGC are present at the MTJ versus the NMJ. Whereas Dystrophin
is the predominant protein that connects the actin cytoskeleton to the transmembrane protein
Dystroglycan (DG) at the MTJ (Ervasti and Campbell, 1993), Utrophin mainly establishes this
connection at the NMJ (Deconinck et al., 1997). Despite these differences, DG is present and
highly glycosylated at both the MTJ and the NMJ. DG glycosylation is required for DG binding to
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basement membrane proteins such as laminin, agrin, and perlecan (Briggs et al., 2016; Gee et
al., 1994; Martin, 2006). Dystroglycanopathies result from mutations in genes responsible for
glycosylation of alpha-DG (DG contains two subunits: a transmembrane beta subunit and an
extracellular alpha subunit) (Godfrey et al., 2011; Inamori et al., 2012; Muntoni et al., 2011).
Thus far, 16 gene products that participate in DG glycosylation have been identified (Nickolls
and Bönnemann, 2018). In addition to muscle degeneration, dystroglycanopathies are
frequently associated with central nervous system defects such as intellectual disability and
brain malformation (Nickolls and Bönnemann, 2018). The role of DG glycosylation in the
peripheral nervous system is less understood although abnormal NMJs have been reported after
birth in a couple dystroglycanopathy mouse models (Côté et al., 1999; Herbst et al., 2009;
Levedakou et al., 2005; Pratt et al., 2015; Saito et al., 2007). Because NMJ defects have been
observed after embryonic development, the most prevalent hypothesis is that post-synaptic DG
does not play a role in NMJ formation, but is important for NMJ stabilization (Nickolls and
Bönnemann, 2018). For example, patients with mutations in GMPPB (required for GDP-mannose
formation (Jensen et al., 2015)), show decreased action potentials with repeated nerve
stimulation (Johnson et al., 2018). Given the plethora of glycosylated proteins at the NMJ, it is
possible that a subset of dystroglycanopathy genes may be required outside of muscle tissue for
NMJ development.
FKRP-associated dystroglycanopathy results from mutations in FKRP, which encodes an
enzyme critical for DG glycosylation. FKRP works in concert with Fukutin to use CDP-ribitol
synthesized by Isoprenoid Synthase Domain-Containing (ISPD) protein to form a tandem ribitol5-phosphate (Gerin et al., 2016; Kanagawa et al., 2016) that links xylose with Nacetylgalactosamine (Taniguchi-Ikeda et al., 2016). This process is necessary for DG
glycosylation. Patients with FKRP-associated dystroglycanopathy present with phenotypic
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variability; however, muscle weakness and elevated serum creatine kinase are consistently
present (Johnson et al., 2018). Depending on the molecular basis of the FKRP mutation,
individuals with this condition may develop limb-girdle muscular dystrophy 2I (LGMD2I) or
congenital muscular dystrophy with or without eye and brain involvement (Stensland et al.,
2011; Van Reeuwijk et al., 2010). There is some genotype-phenotype correlation in patients with
C-terminal FKRP mutations tending to be more severe (Beltran-Valero de Bernabé et al., 2004;
de Bernabé et al., 2003; Stensland et al., 2011; Van Reeuwijk et al., 2010). However, there is
remarkable phenotypic variation among individuals with the same mutation (Stensland et al.,
2011). For example, a study of 25 patients homozygous for c826C/A found significant variation in
muscle pathology, and levels of glycosylated DG (Stensland et al., 2011). Neither the
histopathological alterations nor levels of DG glycosylation correlated with age of onset or
walking function. Interestingly, whereas one set of siblings presented with similar clinical and
histopathological features, a second set of siblings had dramatic variation in the age of onset (12
vs 27 years old) (Stensland et al., 2011). These data suggest that there are modifying factors environmental and/or genetic - that affect progression of FKRP-associated dystroglycanopathy.
These data also suggest that it is imperative to study features other than muscle pathology
and/or levels of DG glycosylation. Mouse (Ackroyd et al., 2009) and zebrafish models of FKRP
deficiency have been used to study mechanisms associated with FKRP-associated
dystroglycanopathy. Zebrafish models of FKRP-associated dystroglycanopathy include
morpholino (MO) models (Kawahara et al., 2010; Thornhill et al., 2008) and a more recently
generated fkrp mutant (Serafini et al., 2018). These studies indicate that the fkrp morphants
phenocopy the fkrp mutant, fkrp deficiency results in impaired muscle development and
wasting, and that laminin deposition at the MTJ is disrupted in Fkrp-deficient zebrafish.
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Laminin is a major component of the basement membrane that surrounds muscle.
Laminin is a heterotrimeric protein with an alpha, beta, and gamma chain. Adhesion of muscle
fibers to laminin is necessary for muscle development and homeostasis (Bajanca et al., 2006;
Gupta et al., 2012; Hall et al., 2007; Smith et al., 2017; Snow et al., 2008b; Yurchenco et al.,
2018). The principle laminin isoform in mature vertebrate skeletal muscle is laminin-211 (alpha2
beta1 gamma1). Mutations in the human laminin alpha2 gene result in MDC1A, a common
congenital muscular dystrophy (Helbling-Leclerc et al., 1995). A different laminin isoform,
laminin-111, is the major isoform expressed during muscle development and laminin-111 is
required for muscle development in mouse and zebrafish (Bajanca et al., 2006; Snow et al.,
2008b). Laminin-111 can partially compensate for laminin-211. Overexpression of laminin
alpha1 slows the progression of dystrophy in laminin alpha2 mutant mice (Gawlik et al., 2004;
Rooney et al., 2012). Injection of laminin-111 protein directly into muscle of mdx mice modeling
Duchenne muscular dystrophy (DMD) improves muscle structure and function (Rooney et al.,
2009). These data indicate that understanding mechanisms that mediate laminin-111 expression
and polymerization during muscle development could provide information for future
therapeutic development. We identified a novel pathway required for laminin-111 organization
at the zebrafish MTJ during muscle development. We found that Nicotinamide Riboside Kinase
2b (previously called muscle Integrin binding protein (Li et al., 1999; Li et al., 2003)) is necessary
for normal laminin-111 organization (Goody et al., 2010). Yeast and human Nrk2s function in an
alternative salvage pathway that generates Nicotinamide Adenine Dinucleotide (NAD+)
(Bieganowski and Brenner, 2004; Tempel et al., 2007). Exogenous NAD+ rescues MTJ
morphogenesis in Nrk2b-deficient zebrafish, indicating that zebrafish Nrk2b also functions to
generate NAD+ (Goody et al., 2010). Given that NAD+ biosynthesis is necessary for normal
laminin-111 organization during muscle development, we asked whether exogenous NAD+
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would be sufficient to improve muscle structure and function in zebrafish modeling muscular
dystrophies. We showed that NAD+ supplementation increases laminin organization and reduces
muscle degeneration in zebrafish deficient for either of the laminin-211 receptors (DG or Integrin
alpha7 (Itga7)) (Goody et al., 2012). As vitamin B3 is a precursor for NAD+, we asked whether
vitamin supplementation would increase NAD+ and improve muscle structure and function in
DG-deficient zebrafish. Indeed, we found that supplementation with EmergenC packets that
contain B vitamins (chosen because they are water soluble) improves muscle structure and
motility in DG-deficient zebrafish.
The two major transmembrane receptors that anchor muscle cells to laminin in their
ECM are DG (described above) (Ervasti and Campbell, 1993; Gee et al., 1994) and Integrin alpha7
(Itga7) (Cohn et al., 1999; Song et al., 1993). Itga7 is also required for muscle homeostasis:
mutations in Itga7 lead to congenital muscular dystrophy with Itga7 deficiency (Hayashi et al.,
1998). These two cell adhesion complexes display some degree of functional redundancy in both
zebrafish and mouse models. Pharmacologically increasing levels of Itga7 compensates for the
loss of Dystrophin in a mouse model of DMD (Sarathy et al., 2017; Van Ry et al., 2015). Given
that NAD+ is sufficient to improve muscle structure in zebrafish deficient for either laminin
receptor complex (DG or Itga7), we hypothesized that NAD+ increases laminin organization by
increasing clustering of the remaining receptor (Goody et al., 2012). Our model is that in the
absence of Itga7, NAD+ increases DG clustering, thus improving muscle-ECM adhesion. Similarly,
we hypothesize that in the absence of DG, NAD+ increases Itga7 clustering, thus improving
muscle-ECM adhesion. This model leads to the question of whether, if DG is present but
hypoglycosylated, NAD+ would be sufficient to improve muscle structure in a zebrafish
secondary dystroglycanopathy model. Our previous data showed beneficial effects of NAD+
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when administered prior to muscle development (Goody et al., 2012). Whether NAD+ is
beneficial after initial muscle development in this context has not yet been determined.
Paxillin is an Integrin-associated adaptor protein that concentrates at the MTJ during
muscle development (Crawford et al., 2003). Paxillin is an essential signaling nexus that
regulates cell adhesion, morphology, and migration (Deakin and Turner, 2008). Paxillin
participates in the Nrk2b-laminin pathway. Nrk2b is cell-autonomously required for subcellular
concentration of Paxillin at the MTJ; and Paxillin overexpression rescues muscle development
Nrk2b-deficient zebrafish (Goody et al., 2010). DG is required for normal Paxillin concentration
at the MTJ: DG-deficient zebrafish show reduced concentration of Paxillin at the MTJ. Addition
of NAD+ improves Paxillin concentration at the MTJ and Paxillin overexpression reduces muscle
degeneration in DG-deficient zebrafish (Goody et al., 2012). In contrast, Paxillin overexpression
does not rescue zebrafish deficient for Itga7 (Goody et al., 2012). These data suggest that
Paxillin functions downstream of NAD+ to improve muscle resilience in DG-deficient zebrafish.
However, whether Paxillin concentration at the MTJ is disrupted in zebrafish models of
secondary dystroglycanopathy and whether Paxillin overexpression ameliorates muscle
degeneration in zebrafish models of secondary dystroglycanopathy have not been investigated.
We used the fkrp morphant model of FKRP-associated dystroglycanopathy (Kawahara et
al., 2010; Thornhill et al., 2008) to address unanswered questions regarding NAD+ regulation of
the ECM in a secondary dystroglycanopathy. In addition, given the data indicating that there is
not a strict correlation between DG glycosylation levels and phenotype, we investigated
neuromuscular junction development in fkrp morphants. We found that supplementing fkrp
morphants with NAD+ at gastrulation improves laminin polymerization at the MTJ, muscle
structure, and muscle function. Despite the fact that Paxillin localization is disrupted in fkrp
morphants, Paxillin overexpression failed to rescue any of these phenotypes. Early NMJ
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development was disrupted in fkrp morphants and improved with NAD+. To our knowledge, this
is the first report of initial NMJ development being disrupted in an animal model of secondary
dystroglycanopathies. As initial NMJ development has not been investigated in an animal model
of DG deficiency, we analyzed early NMJ development in dag1 morphants. We found that NMJ
development is disrupted in dag1 morphants, although to a lesser extent than fkrp morphants.
In contrast to fkrp morphants, NAD+ supplementation did not improve NMJ development in
dag1 morphants. Finally, we show that muscle-specific overexpression of fkrp improved MTJ
morphology but was not sufficient to improve muscle structure or function. Taken together,
these data indicate that, at least in the zebrafish, FKRP-associated dystroglycanopathy does not
phenocopy DG-deficiency. Furthermore, these data show that Fkrp is required for normal NMJ
development and is required in tissues other than muscle.
2.2. Results
2.2.1. NAD+ supplementation prior to muscle development improves muscle and MTJ
structure
Injection of previously published fkrp MOs recapitulated the previously described
phenotype of fkrp morphants (Kawahara et al., 2010; Thornhill et al., 2008) and the recently
described fkrp mutant (Serafini et al., 2018). In agreement with previous findings, multiple
aspects of muscle development are disrupted in fkrp morphants: MTJs are significantly wider
than in control embryos (Fig. 2.1M), muscle fibers are disorganized (Fig. 2.1L), and muscle
degeneration is observed (Fig. 2.1H, N). Muscle fiber adhesion to the MTJ and ECM organization
at the MTJ are disrupted in fkrp morphants (Kawahara et al., 2010; Lin et al., 2011; Thornhill et
al., 2008). We also found that laminin (Fig. 2.1A-B, J) is reduced in fkrp morphants compared to
controls and that beta-DG is concentrated at the MTJ, although sometimes slightly reduced (Fig.
2.1D-E, K). We next asked whether muscle function was disrupted by quantifying the number of
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Figure 2.1. NAD+ or EmergenC supplementation at gastrulation improves muscle structure and
function in fkrp morphants. (A-C) Anterior left, dorsal top, side-mounted embryos at 26 hpf
stained for laminin-111 (purple) and actin (phalloidin, green). (A, A1) Control embryo. Laminin is
concentrated at the MTJ. (B, B1) fkrp morphant. Although laminin is present at the MTJ (white
arrow), it is also present within the myotome (white arrowhead). (C, C1) fkrp morphant treated
with NAD+ at 6 hpf. Laminin is concentrated at the MTJ (white arrow) as in control embryos. (DF1) Anterior left, dorsal top, side-mounted embryos at 72 hpf stained for beta-DG (red) and factin (phalloidin, green). (D, D1) Control embryo. (E, E1) fkrp morphant. Beta-DG staining
appears weaker at the MTJ (white arrowhead). (F, F1) fkrp morphant treated with EmergenC at
6 hpf. Beta-DG staining appears stronger at the MTJ (white arrow). (G-I) Anterior left, dorsal top,
side-mounted embryos at 72 hpf stained for f-actin (phalloidin, gray). (G) Control embryo. (H)
fkrp morphant. White arrowheads indicate single detached fibers. (I) fkrp morphant treated
with EmergenC at 6 hpf. Note the improved muscle fiber structure. (J) Relative staining intensity
of laminin-111 at the MTJ in 26 hpf embryos, based on no staining/localization (none, white),
weak staining/localization (weak, light gray), and strong staining/localization (strong, dark gray)
(images were blinded prior to analysis, see methods). Controls (n=23 embryos) have greater
laminin intensity staining than fkrp morphants (n=32 embryos). NAD+ (n=10 embryos) and
EmergenC (n=30 embryos) supplementation improve laminin-111 concentration at the MTJ in
fkrp morphants. (K) Relative staining intensity of beta-DG at the MTJ in 72 hpf embryos, based
on weak staining (weak, light gray) and strong staining (strong, dark gray). Although fkrp
morphants have more embryos with weaker beta-DG staining at the MTJ (n=7 embryos), there is
no significant difference in beta-DG at the MTJ between untreated morphants, morphants
treated with NAD+ (n=7 embryos), EmergenC (n=7 embryos), or control morphants (n=5
embryos). (L) Quantification of muscle organization at 72 hpf. The anisotropy factor in embryos
injected with fkrp MOs (n=96 half-myotomes) is reduced compared to uninjected controls (n=16
half-myotomes), and NAD+ (n=40 half-myotomes) significantly increases the anisotropy factor in
fkrp morphants. (M) Quantification of MTJ angles at 72 hpf. Injection of fkrp MOs (n=343 MTJs)
significantly increases MTJ angles compared to uninjected controls (n=98 MTJs). Either NAD+
(n=105 MTJs) or EmergenC (n=158 MTJs) treatment significantly reduces MTJ angles compared
to untreated morphants. (N) Untreated fkrp morphants (n=54 embryos) have a significantly
higher percent of myotomes per embryo with fiber detachments than controls (n=40 embryos)
at 72 hpf. NAD+ (n=31 embryos) supplementation significantly reduces the percent of
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myotomes with dystrophy per embryo. (O) Injection of fkrp MOs (n=184 embryos) significantly
increases the number of touches required to induce an escape response compared to
uninjected controls (n=185 embryos). NAD+ (n=84 embryos) or EmergenC (n=111 embryos)
treatment significantly reduces the number of touches to invoke an escape response. Scalebars
are 50 micrometers. *p<0.05, **p<0.01, ***p<0.001, ns non-significant.
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touches required to induce an escape response. We found that fkrp morphants have reduced
muscle function in that they require significantly more touches to induce an escape response
(Fig. 2.1O). These data indicate that fkrp is necessary for normal muscle development and
function.
We previously showed that either NAD+ or EmergenC supplementation at gastrulation is
sufficient to improve ECM organization, reduce muscle degeneration, and improve motility in
dag1 morphants (Goody et al., 2012). We hypothesized that NAD+/EmergenC increased laminin
organization by potentiating clustering of the other major laminin receptors in muscles,
Integrins alpha6/beta1 and alpha7/beta1. We asked if NAD+/EmergenC is sufficient to improve
laminin organization in the context of impaired DG glycosylation because hypoglycosylated DG
could hinder increased laminin organization. We found that NAD+ or EmergenC
supplementation at gastrulation increased the concentration of laminin at the MTJ (Fig. 2.1C, J),
decreased MTJ angles (Fig. 2.1M), decreased muscle degeneration (Fig. 2.1N), improved muscle
fiber organization (Fig. 2.1L), and significantly reduced the touches required to evoke an escape
response (Fig. 2.1O). These data indicate that NAD+ or EmergenC supplementation during
gastrulation is sufficient to improve muscle development and function in Fkrp-deficient
zebrafish.
2.2.2. NAD+/EmergenC are not sufficient to improve vascularization, midbrain-hindbrain
development, or the increased unfolded protein response in fkrp morphants
Fkrp is required for normal zebrafish vascularization: fkrp morphants and the recently
described fkrp mutant exhibit shorter intersegmental vessel (ISV) lengths compared to wild-type
embryos (Serafini et al., 2018; Wood et al., 2011). Fli1:EGFP transgenics injected with fkrp MOs
exhibited shorter ISV lengths (including truncated vessels) than uninjected controls (Fig. 2.2E-F,
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Figure 2.2. NAD+ and EmergenC supplementation at gastrulation do not significantly improve
the UPR or vascularization in fkrp morphants. (A-C1) Anterior left, dorsal top, side-mounted 3
dpf (72 hpf) embryos expressing Tg(ef1α:xbp1δ-GFP). Fluorescence intensity was kept constant
within an experiment (see methods). Numbered panels are merged with the brightfield channel.
(A-A1) Control embryo. Note low relative expression of Xbp1 compared to morphants. (B-B1)
fkrp morphant. (C-C1) fkrp morphant treated with EmergenC at gastrulation. Note that
fluorescence intensity is similar to that of untreated morphant. (D) Quantification of Xbp1
fluorescence intensity normalized to control fluorescence intensity for all groups imaged.
Fluorescence intensity is significantly increased in morphants. There is no significant difference
in fluorescence intensity between untreated morphants (n=15 embryos) and morphants
receiving EmergenC (n=21 embryos). (E-G) Anterior left, dorsal top, side-mounted 2 dpf
embryos expressing Tg(fli1:EGFP) focused on the ISVs. (E) Control embryo. (F) fkrp morphant
embryo. Note that some ISVs are truncated (white arrowhead). (G) fkrp morphant embryo
treated with NAD+ at gastrulation. Truncated ISVs are still present in NAD+ treated morphants
(white arrowhead). (H) Quantification of ISV length. ISV length is reduced in fkrp morphants
(n=201 vessels) compared with uninjected controls (n=84 vessels). NAD+ supplementation
(n=166 vessels) does not rescue ISV length in fkrp morphants. Scalebars are 50 micrometers.
*p<0.05, **p<0.01, ***p<0.001, ns non-significant.
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H). NAD+ supplementation had no significant effect on ISV length in fkrp morphants (Fig. 2.2GH). We also analyzed ISV length when normalized to the width of the embryos because muscle
development is disrupted in fkrp morphants. The same result was observed with normalized
data (not shown). These data suggest that: (1) NAD+ supplementation is not sufficient to
improve vascularization in fkrp morphants, and (2) the vascularization defects observed in fkrp
morphants are likely a consequence of fkrp knockdown and not aberrant muscle development
and/or homeostasis.
Zebrafish deficient for Fkrp exhibit abnormal midbrain-hindbrain boundary formation
that has been likened to cobblestone lissencephaly (Thornhill et al., 2008). We also observed
abnormal midbrain-hindbrain boundary formation in fkrp morphants at 26 hpf (n = 8 embryos)
compared with uninjected controls. NAD+ was not sufficient to rescue midbrain-hindbrain
boundary formation (n = 8 embryos, data not shown). Zebrafish models of FKRP-associated
dystroglycanopathy are also associated with endoplasmic reticulum (ER) stress and activation of
the unfolded protein response (UPR) (Lin et al., 2011). One marker of the UPR is increased
activation of the xbp1 transcript, which is upregulated in fkrp morphants (Lin et al., 2011) and
the recently described fkrp mutant (Serafini et al., 2018). To determine whether EmergenC
could improve ER stress in fkrp morphants, we injected fkrp MOs into the Tg(ef1α:xbp1δ-GFP)
line that allows visualization of xbp1 activation (Li et al., 2015). Injection of fkrp MOs increased
the UPR (Fig. 2.2B) compared with controls (Fig. 2.2A). However, untreated and EmergenC
treated fkrp morphants did not significantly differ in relative fluorescence intensity (Fig. 2.2C-D).
Taken together, these results suggest that the benefits of NAD+ supplementation may be limited
to muscle in Fkrp-deficient zebrafish.
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Figure 2.3. Paxillin overexpression does not improve muscle structure in fkrp morphants. (AB3) Anterior left, dorsal top, side-mounted embryos at 26 hpf stained for Paxillin (green) and factin (purple). Paxillin concentrates at the MTJ (white arrowhead) in control embryos. There are
some gaps in Paxillin localization in fkrp morphants (B2, white arrow) and Paxillin accumulates at
the muscle pioneers (B2, white asterisk). (C-E2) Anterior left, dorsal top, side-mounted embryos
at 72 hpf stained for f-actin (phalloidin, gray) in lettered and even numbered panels and
expressing Paxillin-EGFP (green) in numbered panels. (C-C2) A fkrp morphant with disorganized
muscle fibers. (D-D2) Control Tg(hsp70l:pxna-EGFP) embryo expressing Paxillin which
concentrates at the MTJ (white arrowhead). (E-E2) Tg(hsp70l:pxna-EGFP) fkrp morphant. (F) MTJ
angle quantification. Fkrp morphants with (n=241 MTJs) and without (n=170 MTJs) Paxillin-EGFP
expression have a significant increase in average MTJ angle width compared with uninjected
controls (n=189, 191 MTJs). Paxillin overexpression in fkrp morphants significantly increases MTJ
angles compared to morphants that do not overexpress Paxillin. (G) Fiber degeneration
quantification. Fkrp morphants with (n=55 embryos) and without (n=60 embryos) Paxillin-EGFP
expression have a significant increase in the percent of myotomes with degeneration per
embryo compared to uninjected controls (n=57, 54 embryos). Although there is a trend, Paxillin
overexpressing morphants do not have a significant reduction in dystrophy compared to control
fkrp morphants. (H) Escape response quantification. Fkrp morphants with (n=88 embryos) and
without (n=70 embryos) Paxillin-EGFP expression require significantly more touches to induce
an escape response compared with uninjected controls (n=66, 80 embryos). Fkrp morphants
overexpressing Paxillin do not exhibit a significant improvement in escape response compared
with fkrp morphants that do not overexpress Paxillin. Scalebars are 50 micrometers. *p<0.05,
**p<0.01, ***p<0.001, ns non-significant.
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2.2.3. Paxillin overexpression does not significantly reduce muscle degeneration
Paxillin is an Integrin-associated protein that is required for cell adhesion to the ECM
(Turner et al., 1990). Paxillin concentrates at MTJs in wild-type muscle ((Crawford et al., 2003),
Fig. 2.3). Paxillin plays a role in the Nrk2b-NAD+-laminin cell adhesion pathway. Paxillin
concentration at the MTJ is disrupted in nrk2b morphants and rescued with NAD+ (Goody et al.,
2010). Paxillin overexpression rescues nrk2b morphants (Goody et al., 2010). Similarly,
concentration of Paxillin at the MTJ is disrupted in dag1 morphants and is improved with NAD+.
Paxillin overexpression improves muscle structure in dag1 morphants (Goody et al., 2012). It is
not known if either Paxillin concentration at the MTJ is disrupted in animal models of secondary
dystroglycanopathy or if Paxillin overexpression improves muscle structure in these models. We
found that Paxillin concentration at the MTJ was disrupted in 26 hpf fkrp morphants (Fig. 2.3B)
compared with controls (Fig. 2.3A). Paxillin does concentrate at the center of the MTJ adjacent
to muscle pioneers that are slow-twitch fibers (Fig. 2.3B at the crux of the v-shaped MTJ, this
was observed in 14/16 fkrp morphants). However, Paxillin concentration at the MTJ adjacent to
fast-twitch muscle is disrupted (Fig. 2.3B2, arrow). These data suggest that Fkrp is required for
normal development of the MTJ adjacent to fast-twitch muscle. Overexpression of Paxillin was
sufficient for Paxillin to concentrate at the fast-muscle MTJ in fkrp morphants (Fig. 2.3E1
arrowhead). However, in contrast to what we previously observed in dag1 morphants (Goody et
al., 2012), Paxillin overexpression did not reduce muscle degeneration or improve the escape
response in fkrp morphants (Fig. 2.3G-H). Paxillin overexpression actually increased MTJ angles
(Fig. 2.3F). These data indicate that, in contrast to dag1 morphants, Paxillin overexpression is
not sufficient to improve muscle structure in fkrp morphants.
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Figure 2.4. Later NAD+ supplementation improves MTJ structure, but NAD+ and EmergenC are
required prior to initial muscle development to improve motility, fiber resilience, and fiber
organization. (A-D) Anterior left, dorsal top, side-mounted embryos at 72 hpf stained for f-actin
(phalloidin, gray). (A) Control embryo. (B) fkrp morphant. (C) fkrp morphant treated with NAD+
at 24 hpf. (D) fkrp morphant treated with EmergenC at 24 hpf. White arrowheads indicate single
fiber detachments. (E) Fiber organization quantification. The anisotropy factor in embryos
injected with fkrp MOs (n=104 half-myotomes) is reduced compared to controls (n=48 halfmyotomes) and not improved with NAD+ supplementation at 24 hpf (n=96 half-myotomes). (F)
MTJ angle quantification. Fkrp morphants treated with NAD+ (n=381 MTJs) or EmergenC (n=318
MTJs) at 24 hpf have significantly decreased MTJ angles compared to untreated morphants
(n=651 MTJs). (G) Fiber detachment quantification. Although there is a trend towards reduced
muscle degeneration, fkrp morphants receiving NAD+ (n=55 embryos) or EmergenC (n=41
embryos) at 24 hpf do not have a significant reduction in the percent of myotomes with
dystrophy compared to untreated morphants (n=98 embryos). (H) Escape response
quantification. The number of touches required to induce an escape response is elevated in
embryos injected with fkrp MOs (n=128 embryos) compared to controls (n=114 embryos).
Morphants treated with NAD+ at 24 hpf (n=81 embryos) have a worsened escape response
compared to untreated morphants. Morphants treated with EmergenC at 24 hpf (n=52
embryos) do not exhibit a significant change in escape response compared to untreated
morphants, but significantly differ from NAD+ treated morphants. Scalebars are 50
micrometers. *p<0.05, **p<0.01, ***p<0.001, ns non-significant.
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2.2.4. NAD+ supplementation after initial muscle development improves MTJs, but not muscle
structure
NAD+/EmergenC supplementation prior to muscle development is sufficient to improve
muscle structure and function in dag1 (Goody et al., 2012) and fkrp morphant embryos (Fig.
2.1). It is not known whether NAD+ or EmergenC can improve muscle structure and function
after initial muscle development. We supplemented fkrp morphants with NAD+ or EmergenC at
24 hpf (after initial muscle development). Both NAD+ and EmergenC supplementation
significantly improved MTJ angles (Fig. 2.4F). In contrast, neither NAD+ nor EmergenC
supplementation at 24 hpf was sufficient to improve muscle fiber organization, reduce muscle
degeneration, or improve the escape response (Fig. 2.4A-D, E, G, H). Thus, NAD+/EmergenC
supplementation after initial muscle development is not sufficient to ameliorate muscle
degeneration and improve muscle function in Fkrp-deficient zebrafish embryos.
2.2.5. NMJ development is disrupted and partially improved with NAD+ supplementation in
fkrp morphants
The DGC is necessary for NMJ maturation after birth in mouse (Herbst et al., 2009;
Jayasinha et al., 2003; Levedakou et al., 2005). DG glycosylation is also necessary for normal
NMJ formation during muscle regeneration (Goddeeris et al., 2013). It is generally thought that
DG is not required for NMJ development but is required for NMJ maturation/stabilization/
regeneration (Gumerson et al., 2013). We asked whether initial NMJ development is disrupted
in secondary dystroglycanopathies. We analyzed NMJ structure at 72 hpf by staining for SV2 and
postsynaptic AChRs (alpha-bungarotoxin). We focused on analysis of innervation of fast-twitch
fibers (distributed innervation, see skeletons Fig. 2.5). There is an extensive network of
distributed NMJs in 72 hpf control embryos (Fig. 2.5A). This network is qualitatively disrupted in
fkrp morphants where there appeared to be shorter chains of NMJs (Fig. 2.5B). Supplementation
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Figure 2.5. Fkrp morphants exhibit NMJ defects and NAD+ and EmergenC treatment prior to
muscle development improves NMJ development. (A-D4) Anterior left, dorsal top, sidemounted embryos at 72 hpf with labeled AChR and SV2. (Lettered panels) Merged channels of
AChR and SV2. (1) Skeletonized images. (2) Magnification of SV2 channel. (3) Magnification of
AChR channel. (4) Magnification of skeleton channel. (A-A4) Control embryo. (B-B4) fkrp
morphant embryo exhibiting reduced distributed innervation within the myotome. (C-C4) fkrp
morphant embryo treated with NAD+ at 6 hpf shows increased NMJs. (D-D4) fkrp morphant
embryo treated with EmergenC at 6 hpf also shows increased NMJs. (E) Length of skeletons.
Skeleton length is reduced in fkrp morphants (n=153 half-myotomes) compared to controls
(n=144 half-myotomes), but significantly increased in fkrp morphants receiving NAD+ (n=183
half-myotomes) or EmergenC (n=127 half-myotomes) at 6 hpf. (F) Degree of branching within
the myotome in control embryos (n=141 half-myotomes), fkrp morphants (n=147 halfmyotomes), and fkrp morphants receiving NAD+ (n=179 half-myotomes) or EmergenC (n=126
half-myotomes) at 6 hpf. Scalebars are 50 micrometers. *p<0.05, ns non-significant.
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of NAD+ or EmergenC improved NMJ length, although NMJs were not fully restored (Fig. 2.5CD). In order to quantify innervation, we developed a semi-automated technique in MATLAB to
skeletonize NMJs (see Chapter 5, Section 5.10.8). This analysis showed that although branching
frequency was normal, skeleton length was reduced in fkrp morphants (Fig. 2.5E, F). NAD+ or
EmergenC supplementation at 6 hpf slightly, but significantly, improved skeleton length in fkrp
morphants (Fig. 5E). These results suggest that Fkrp is necessary for innervation, but not
branching.
As mentioned above, DG contributes to NMJ maturation and stabilization (Gumerson et
al., 2013). Given the above data showing that initial NMJ development is disrupted in fkrp
morphants, we asked whether DG is also required for NMJ development. We found that
skeleton length was slightly, but significantly, reduced in dag1 morphants (Fig. 2.6B) compared
to controls (Fig. 2.6A). However, NAD+ supplementation at gastrulation did not significantly
increase skeleton length in dag1 morphants despite rescuing other aspects of the phenotype
(Fig. 2.6C-D, F). This result contrasts with what we observed in fkrp morphants supplemented
with NAD+. Thus, we compared the relative severity of NMJ skeleton length defects in fkrp
morphants versus dag1 morphants. On average, dag1 morphant skeleton length was 83.9% of
that of uninjected controls. In contrast, fkrp morphant skeleton length on average was 51.4% of
that of uninjected controls (Fig. 2.6G). Thus, NMJs are more severely disrupted in fkrp
morphants compared to dag1 morphants.
Somewhat surprisingly, we found that NAD+ supplementation at 24 hpf actually
significantly worsened the escape response in fkrp morphants (Fig. 2.4, p<0.05) despite the fact
that we did not observe a significant deterioration of muscle structure. Thus, we asked how
NAD+ supplementation at 24 hpf affected NMJ structure (Fig. 2.7). We found that the effects of
NAD+ on NMJ structure correlated with the motility defects: NAD+ at 24 hpf resulted in
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Figure 2.6. Skeleton length is less disrupted in dag1 morphants than in fkrp morphants and is
not significantly improved with NAD+ supplementation. (A-C6) Anterior left, dorsal top, sidemounted embryos at 72 hpf with labeled actin, AChRs, and SV2. (Lettered panels) Phalloidin
stained embryos. (1) Merged channels of AChR and SV2. (2) Skeletonized images. (3)
Magnification of phalloidin channel. (4) Magnification of SV2 channel. (5) Magnification of AChR
channel. (6) Magnification of skeleton channel. (A-A6) Control embryo. (B-B6) dag1 morphant
embryo. (C-C6) dag1 morphant embryo treated with NAD+ at 6 hpf. (D) Length of skeletons per
myotome in control embryos (n=186 half-myotomes), dag1 morphants (n=260 half-myotomes),
and dag1 morphants receiving NAD+ (n=252 half-myotomes) at 6 hpf. Skeleton length is not
significantly different between untreated and NAD+ treated dag1 morphants. (E) Degree of
branching within the myotome in control embryos (n=180 half-myotomes), dag1 morphants
(n=254 half-myotomes), and dag1 morphants receiving NAD+ (n=249 half-myotomes) at 6 hpf.
NAD+ treatment made no significant difference. (F) MTJ angle quantification. MTJ angles are
significantly reduced in dag1 morphants receiving NAD+ (n=98 MTJs) compared to untreated
dag1 morphants (n=97 MTJs). (G) Bar graph of the percent skeleton length of control embryos
per myotome. Note that the average percent skeleton length is more drastically reduced in fkrp
morphants (51.4%, n=153 half-myotomes) than in dag1 morphants (83.9%, n=260 halfmyotomes). NAD+ supplementation increased this percentage in fkrp morphants (61.9%, n=183
half-myotomes), but has little effect on dag1 morphants (85.0%, n=252 half-myotomes)
Scalebars are 50 micrometers. Error bars in (G) are standard error of the mean. *p<0.05,
**p<0.01, ***p<0.001, ns non-significant.
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significantly shorter skeleton lengths (Fig. 2.7E). There was no significant difference between 24
hpf treated and untreated morphants in terms of branching frequency (Fig. 2.7F).
2.2.6. Muscle specific FKRP expression is not sufficient to rescue fkrp morphants
The above data indicate that Fkrp is necessary for early NMJ development and that
disruption in NMJ morphology with 24 hpf NAD+ treatment correlates with worse motility.
These results raise the possibility that Fkrp function is required in non-muscle tissues. We tested
this hypothesis by expressing Fkrp in a muscle-specific manner. To confirm that constitutive Fkrp
overexpression could rescue fkrp morphants, we injected fkrp MOs into a Tg(hsp70l:fkrp-EGFP)
line we generated (Fig. 2.8A). Previous data suggest that overexpression of fkrp can be
deleterious (Vannoy et al., 2017). Although we observed a slight increase in MTJ angles (Fig.
2.8C), we did not observe any significantly adverse effects of Fkrp-EGFP on fiber degeneration or
the escape response in control embryos (expression was induced at the 15 somite stage) (Fig.
2.8A, D-E). Global overexpression of Fkrp-EGFP in fkrp morphants improved fiber resiliency, MTJ
angles, and the escape response compared to control morphants (Fig. 2.8B-E). These data
indicate that: (1) overexpression of Fkrp is not toxic under these conditions, and (2) EGFP does
not deleteriously affect Fkrp function. We next asked whether muscle-specific expression was
sufficient to rescue the phenotype. We generated a transgenic line expressing Fkrp-EGFP under
control of the -503unc promoter (Berger and Currie, 2013). Muscle-specific overexpression of
Fkrp did not affect muscle morphology in control embryos (Fig. 2.8F-F2). Muscle-specific
overexpression of Fkrp in fkrp morphants decreased MTJ angles compared to EGFP negative
control morphants (Fig. 2.8I). However, no other metrics of muscle structure/function were
improved. Muscle specific overexpression neither ameliorated fiber detachment (Fig. 2.8G-H, J)
nor reduced touches required to induce an escape response (Fig. 2.8K). These data indicate that
expression of Fkrp in muscle is not sufficient to rescue muscle morphology or function.
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Figure 2.7. Supplementation with NAD+ or EmergenC after muscle development does not
improve NMJ morphology in fkrp morphants. (A-D4) Anterior left, dorsal top, side-mounted
embryos at 72 hpf with labeled AChRs and SV2. (Lettered panels) Merged channels of AChR and
SV2. (1) Skeletonized images. (2) Magnification of SV2 channel. (3) Magnification of AChR
channel. (4) Magnification of skeleton channel. (A-A4) Control embryo. (B-B4) fkrp morphant
embryo exhibiting a reduced degree of distributed innervation within the myotome. (C-C4) fkrp
morphant embryo treated with NAD+ at 24 hpf also has reduced innervation. (D-D4) fkrp
morphant embryo treated with EmergenC at 24 hpf has reduced NMJs. (E) Length of skeletons
per myotome in control embryos (n=288 half-myotomes), fkrp morphants (n=303 halfmyotomes), and fkrp morphants receiving NAD+ (n=225 half-myotomes) or EmergenC (n=225
half-myotomes) at 24 hpf. Note that skeleton length is actually significantly decreased in fkrp
morphants receiving NAD+ at 24 hpf. (F) Degree of branching within the myotome in control
embryos (n=283 half-myotomes), fkrp morphants (n=295 half-myotomes), and fkrp morphants
receiving NAD+ (n=221 half-myotomes) or EmergenC (n=210 half-myotomes) at 24 hpf.
Scalebars are 50 micrometers. *p<0.05, ns non-significant.
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2.3. Discussion
Dystroglycanopathies are a relatively understudied subset of muscular dystrophies. One
aspect of dystroglycanopathies that is not well understood is how the myomatrix is impacted.
Whether strategies that improve the myomatrix and muscle structure in a primary
dystroglycanopathy (DG deficiency) are efficacious in secondary dystroglycanopathies are also
not known. We previously showed that either NAD+ supplementation or overexpression of an
Integrin-associated adaptor protein (Paxillin) are sufficient to improve muscle structure and
function in DG-deficient zebrafish. Here we show that muscle phenotypes in a zebrafish model
of FKRP-associated dystroglycanopathy are improved with NAD+ supplementation but not
Paxillin overexpression. Although the mechanisms are not known, these data clearly indicate
that primary and secondary dystroglycanopathies show some differences. Our data also suggest
that there are differences even within secondary dystroglycanopathies. Whereas muscle-specific
expression of Large is sufficient to rescue muscle structure and function in Large/myd mutant
mice (Gumerson et al., 2013), we found that muscle-specific expression of fkrp is not sufficient
to improve muscle structure/function in fkrp morphant zebrafish. Finally, our data show that
NMJ formation is disrupted earlier in development than has previously been observed in a
primary and secondary dystroglycanopathy model. Taken together, these data indicate that it is
necessary to study the secondary dystroglycanopathies individually within the context of the
group as a whole.
2.3.1. Cell-matrix adhesion and secondary dystroglycanopathy
Adhesion of muscle fibers to the MTJ is necessary for muscle development and
homeostasis. We previously identified a cell adhesion pathway that contributes to laminin
organization at the MTJ: Nrk2b-mediated NAD+ production potentiates laminin organization at
the MTJ during zebrafish muscle development (Goody et al., 2010). We then demonstrated that
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Figure 2.8. Muscle-specific overexpression of Fkrp improves MTJ angles, but not motility or
fiber resiliency. (A-B2) Anterior left, dorsal top, side-mounted embryos at 72 hpf stained for factin (phalloidin, gray) and expressing Fkrp-EGFP (green). (A-A2) Control Tg(hsp70l:fkrp-EGFP)
embryo expressing Fkrp in the fibers. (B-B2) fkrp morphant Tg(hsp70l:fkrp-EGFP) embryo
expressing Fkrp in fibers. (C) MTJ angles of Tg(hsp70l:fkrp-EGFP) control (n=264 MTJs) and fkrp
morphant (n=340 MTJs) embryos and AB controls and morphants (n=141, 194 MTJs) at 72 hpf.
Constitutive expression of Fkrp improves MTJ angles in morphants. (D) Constitutive expression
of Fkrp in morphants (n=72 embryos) significantly reduces the number of myotomes with fiber
degeneration compared with control morphants (n=35 embryos). (E) The escape response is
significantly reduced in fkrp morphants constitutively overexpressing Fkrp (n=82 embryos)
compared to control morphants (n=44 embryos). (F-H2) Anterior left, dorsal top, side-mounted
embryos at 72 hpf stained for f-actin (phalloidin, gray) and expressing Fkrp-EGFP under control
of the muscle-specific -503unc promoter (green). (F) Control Tg(-503unc:fkrp-EGFP) embryo
expressing Fkrp specifically in muscle fibers. G) fkrp morphant embryo on Tg(-503unc:fkrp-EGFP)
background lacking Fkrp expression in muscle fibers. (H) fkrp morphant Tg(-503unc:fkrp-EGFP)
embryo expressing Fkrp specifically in muscle fibers does not show improved muscle
organization. (I) Muscle specific expression of FKRP in fkrp morphants (n=158 MTJs) significantly
improves MTJ angles compared to control morphants (n=153 MTJs). (J) Muscle-specific
overexpression of Fkrp (n=45 embryos) does not significantly lower the percent of myotomes
with muscle degeneration in control fkrp morphants (n=47 embryos). (K) There is not a
significant difference in the number of touches required to induce an escape response in fkrp
morphants that overexpress Fkrp (n=73 embryos) in muscle versus those that do not (n=79
embryos). Scalebars are 50 micrometers. *p<0.05, **p<0.01, ns non-significant.
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exogenous NAD+ is sufficient to improve laminin organization, muscle structure, and muscle
function in zebrafish deficient for either DG or Itga7 (Goody et al., 2012). DG and Itga7 are both
transmembrane receptors for laminin. We hypothesized that NAD+ improved laminin
organization, at least in part, by increasing clustering of the remaining receptor (DG in Itga7deficient embryos, and Itga7 in DG-deficient embryos). Here, we asked whether laminin
organization would be increased if DG is present but hypoglycosylated. The rationale was that it
is possible that the presence of hypoglycosylated DG that cannot bind laminin could inhibit the
improvement of laminin organization with NAD+. The ribitol 5-phosphate transferase FKRP is
necessary for proper glycosylation of DG (Gerin et al., 2016; Kanagawa et al., 2016). We asked if
NAD+ was sufficient to improve cell-matrix adhesion in fkrp morphant zebrafish embryos. We
found that NAD+ supplementation prior to muscle development was sufficient to improve
laminin polymerization, muscle structure, and the escape response.
Organization of laminin at the MTJ is disrupted in zebrafish deficient either for DG
(Goody et al., 2012) or Fkrp (Kawahara et al., 2010; Lin et al., 2011; Thornhill et al., 2008) (Fig.
2.1). Laminin is required for concentration of the Integrin adaptor protein Paxillin to the MTJ
(Goody et al., 2010). Paxillin is an intracellular protein that localizes to cell-ECM adhesion
complexes (Deakin and Turner, 2008) and modulates ECM composition at the developing MTJ
(Jacob et al., 2017). Previous data regarding the beneficial potential of Paxillin in the context of
aberrant muscle development/homeostasis are contradictory. Paxillin overexpression worsens
muscle damage in ethanol-treated zebrafish (Coffey et al., 2018). However, Paxillin
overexpression is sufficient to improve MTJ morphology in Nrk2b-deficient zebrafish (Goody et
al., 2010). Paxillin overexpression also improves laminin organization and reduces muscle
degeneration in dag1 morphant zebrafish (Goody et al., 2012). We hypothesized that Paxillin
overexpression would improve muscle structure and function in fkrp morphants where DG is
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present but not properly glycosylated. Interestingly, we found that Paxillin expression trended
towards reducing degeneration and improving the escape response, but the effects were not
significant (Fig. 2.3). This result suggests the hypothesis that, in contrast to the situation where
DG is absent, the presence of hypoglycosylated DG in the membrane prevents Paxillin-mediated
stabilization of muscle fibers.
2.3.2. Benefits of NAD+ supplementation may be restricted to the neuromusculoskeletal
system
Both fkrp morphants and mutants have an increased UPR. Xpb1, a marker of the UPR, is
upregulated in both fkrp morphants and fkrp mutants (Lin et al., 2011; Serafini et al., 2018).
Expression of bip, a marker of the UPR, is upregulated in fkrp morphants at 28 hpf, especially in
the neural floor plate and the hatching gland (Lin et al., 2011). However, glytl1b (large2)
morphants with hypoglycosylated DG, dag1 morphants, and sly/lam1c mutants do not exhibit
bip upregulation (Lin et al., 2011), suggesting that activation of the UPR may result directly from
loss of Fkrp. We asked if EmergenC supplementation was sufficient to reduce the UPR in fkrp
morphants. We found that 3 dpf Tg(ef1α:xbp1δ-GFP) embryos injected with fkrp MOs have
increased xbp1-GFP fluorescence compared to control embryos. EmergenC supplementation at
gastrulation was not sufficient to reduce xbp1-GFP fluorescence. Taken together, these data
suggest that activation of the UPR occurs independently of muscle-cell matrix adhesion and DG
glycosylation and is likely a direct consequence of Fkrp knockdown.
Fkrp morphants and fkrp mutants also exhibit aberrant vascular development, including
reduced ISV lengths (Serafini et al., 2018; Wood et al., 2011). One study suggests that impaired
vascularization directly results from loss of Fkrp and that muscle phenotypes and vascular
phenotypes are independent of one another (Wood et al., 2011). Here, we demonstrate that
NAD+ supplementation at gastrulation is not sufficient to rescue truncated ISVs in fkrp
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morphants. Given that NAD+ improves muscle structure and function in fkrp morphants, our
data suggest that vascular phenotypes observed in fkrp morphants are not dependent on
muscle phenotypes. This supports the previous hypothesis that abnormal vascular development
in zebrafish models of FKRP-associated dystroglycanopathy is a direct result of loss of Fkrp.
2.3.3. Timing of NAD+ intervention is critical
Gene therapy (Qiao et al., 2014; Thomas et al., 2016; Tucker et al., 2018; Vannoy et al.,
2017), estrogen receptor modulators (Wu et al., 2018), and exogenous ribitol supplementation
(Cataldi et al., 2018) improve muscle structure in FKRP-associated dystroglycanopathy models.
The efficacy of adenoviral gene therapy and ribitol supplementation decreases if administered
later in the mouse’s lifespan (Cataldi et al., 2018; Vannoy et al., 2017), suggesting that early
intervention is most beneficial. Our data regarding the timing of NAD+ and EmergenC
supplementation in fkrp morphants are consistent with the data mentioned above. We found
that NAD+ (or EmergenC) supplementation prior to muscle development increased laminin
organization, reduced muscle degeneration, improved muscle function, and improved NMJ
structure (Fig. 2.1). In contrast, NAD+ (or EmergenC) supplementation after initial muscle
development only improved MTJs and not muscle structure/function (Fig. 2.4).
Our data do not resolve why MTJ morphology is improved with late NAD+
supplementation or muscle-specific overexpression of Fkrp. Improved MTJ morphology does not
always correlate with fiber degeneration. Itga7 morphants exhibit muscle fiber detachment but
have normal MTJ morphology, and NAD+ supplementation improves MTJ angles, but not fiber
degeneration in dag1/itga7 double morphants (Goody et al., 2012). Movement is not necessary
for MTJ chevron formation in zebrafish embryos (Rost et al., 2014). We show that motility is not
improved in fkrp morphants receiving NAD+ or EmergenC after initial muscle development,
further suggesting that improved MTJ morphology does not always correlate with mobility.
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While this manuscript was in preparation, it was shown that administration of pentetic
acid at 48 hpf improved muscle and pericardiac phenotypes in a fkrp zebrafish model of LGMD2I
(Serafini et al., 2018). Pentetic acid is a chelating agent that binds Ca2+ and Mg2+. The
mechanism by which this improves muscle phenotypes is currently unknown. However,
abnormal Ca2+ levels have been implicated in DMD and inducing an influx of Ca2+ is sufficient
to induce dystrophy (Millay et al., 2009). Together, these data suggest that different therapeutic
avenues have different time windows of efficacy in multiple animal models.
2.3.4. Dag1 and fkrp are required for proper NMJ development
NMJ development requires orchestrated interactions between muscle cells and motor
neurons. The DGC is a major component of NMJs. Thus, it is not surprising that NMJ morphology
is disrupted in multiple dystroglycanopathies. Fukutin-deficient chimeric mice have abnormal
AChR clustering and NMJs at postnatal day 15 (Saito et al., 2007). Newborn pups homozygous
for Large/myd mutations have altered NMJs as well (Herbst et al., 2009). These data clearly
indicate that NMJs are abnormal after birth. What is not clear is at which point in embryonic
development NMJ disruption occurs. Do NMJs develop normally and then degenerate or is initial
NMJ development abnormal? Here, we provide evidence that early NMJ development is slightly
disrupted in DG-deficient zebrafish, with NMJ chains that innervate fast-twitch muscle being
approximately 84% of control chain length. To our knowledge, this is the earliest developmental
stage at which NMJ disruption has been observed in a primary or secondary dystroglycanopathy.
Interestingly, fkrp morphants exhibit more dramatic disruption of NMJ morphology, with NMJ
chains about half of control chain length. We do not know the mechanisms underlying the more
severe disruption in NMJ development in fkrp versus dag1 morphants. One possibility is that
hypoglycosylated dag1 acts as a “dominant negative” and thus disrupts NMJ development more
than when dag1 is not present. Additionally, there are many glycosylated proteins at the MTJ,
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such as Lrp2, Musk, and Agrin. Thus, the more severe disruption in fkrp morphants could also
reflect a requirement of Fkrp for glycosylation of other NMJ resident proteins.
2.3.5. Muscle-specific overexpression of Fkrp is not sufficient to rescue fkrp morphants
Overexpression of LARGE is sufficient to synthesize glycan-enriched alpha-DG and is
sufficient to improve laminin binding activity in multiple dystroglycanopathy patient cell lines
(Barresi et al., 2004). Muscle-specific expression of Large is sufficient to rescue muscle structure,
neurotransmission, and NMJs in Large/myd mutant mice (Gumerson et al., 2013). NMJ defects
in Large/myd mutant mice were observed after birth (Herbst et al., 2009). The above data
suggest that, in the context of Large-associated Dystroglycanopathy, NMJ defects are secondary
to muscle disruption. Given that we observed very early developmental disruption of NMJs, we
couldn’t necessarily conclude that NMJ disruption in Fkrp-deficient embryos is secondary to the
muscle phenotype. Thus, we tested whether muscle-specific expression of Fkrp would be
sufficient to rescue neuromuscular function in fkrp morphant embryos. We first showed that
global expression of Fkrp (under control of the heat shock promoter) is sufficient to rescue fkrp
morphant embryos. This result indicates that the Fkrp-EGFP fusion protein is functional.
Next, we expressed Fkrp in muscle under control of the muscle specific -503unc
promoter (Berger and Currie, 2013). We found that muscle-specific expression of Fkrp was
sufficient to slightly, but significantly, reduce MTJ angles. However, muscle-specific expression
of Fkrp was not sufficient to reduce muscle degeneration or improve the escape response (Fig.
2.8). We do not know why our results differ from the Large study. We do not believe that timing
of expression is the key factor because muscle creatine kinase (Large study) and Unc45b (our
study) are expressed at similar times during myotome development. In the DG glycosylation
pathway, FKRP works in concert with Fukutin (FKTN) to synthesize a tandem ribitol phosphate
that connects a core o-linked glycan with matriglycan, the ligand for laminin and other ECM
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proteins (Gerin et al., 2016; Kanagawa et al., 2016). This step precedes the completion of
matriglycan synthesis by LARGE. Roles for LARGE or FKRP in other glycosylation reactions have
not been identified. However, the fact that muscle-specific expression of Fkrp is not sufficient to
rescue muscle homeostasis may suggest that Fkrp is required to glycosylate proteins other than
DG. Regardless, our data indicate that Fkrp is required outside of skeletal muscle to reduce
muscle degeneration. In the future it will be interesting to determine in which tissues and cells
Fkrp is required to rescue neuromuscular function in Fkrp-deficient embryos.
2.4. Conclusion
The myomatrix is critical for muscle development and homeostasis and is disrupted in
many dystroglycanopathies studied thus far (Di Costanzo et al., 2014; Lin et al., 2011; Marchese
et al., 2016; Roscioli et al., 2012; Stevens et al., 2013). Here, we primarily focused on two
specialized junctions within the myomatrix: the MTJ and NMJ. MTJ and NMJ development are
disrupted in fkrp morphants. NAD+ supplementation prior to muscle development, which
improves myomatrix organization in DG-deficient zebrafish, was sufficient to improve muscle
homeostasis, MTJ structure, and NMJ formation in fkrp morphant zebrafish. However, NAD+ did
not improve vascular or UPR phenotypes in fkrp morphants, and NAD+ supplementation after
initial muscle development was not particularly efficacious. There was a slight improvement in
MTJ structure and a reduced variation in muscle degeneration. These data are similar to
previous studies showing that earlier intervention has improved outcomes in FKRP mutant mice
(Cataldi et al., 2018; Vannoy et al., 2017). Interestingly, in contrast to muscle-specific expression
of Large in Large/myd mutant mice, muscle-specific overexpression of Fkrp was not sufficient to
improve muscle structure/function in fkrp morphants. Taken together, our data indicate that
Fkrp plays an early and crucial role in muscle, MTJ, and NMJ development.
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CHAPTER 3
PHENOTYPIC VARIATION AND PLASTICITY IN A ZEBRAFISH MODEL OF
GMPPB-ASSOCIATED DYSTROGLYCANOPATHY
3.1. Introduction
Skeletal muscle is a tissue that is conserved among many organisms and is necessary for
strength and locomotion. It is a highly plastic tissue that undergoes changes in size based on
genetic and/or environmental cues. Skeletal muscle may grow in size (hypertrophy) in response
to diet and exercise. However, aging (sarcopenia), cancer cachexia, a lack of exercise, and
neuromuscular diseases such as muscular dystrophies can cause a loss of muscle mass (atrophy).
Individuals with muscular dystrophies and similar conditions often possess remarkable variation
in both the level of muscle atrophy and the ability to regenerate skeletal muscle, even when the
molecular basis of their condition is similar. The mechanisms that contribute to this phenotypic
variation among individuals with the same type of muscular dystrophy remain poorly
understood.
One group of muscular dystrophies where phenotypic variation is common are the
dystroglycanopathies. These are a suite of molecularly distinct conditions that result from
mutations in in genes responsible for glycosylating Dystroglycan (DG) (Godfrey et al., 2011;
Inamori et al., 2012; Muntoni et al., 2011). DG is a major component of the dystrophinglycoprotein complex (DGC) that helps link the actin cytoskeleton of muscle fibers with laminin
and other extracellular matrix (ECM) proteins. It contains a transmembrane beta subunit and an
extracellular alpha subunit that binds to laminin and other ECM proteins (Muntoni et al., 2011).
Alpha-DG must be glycosylated by a team of glycosyltransferases in order to bind to its ligands.
Patients with dystroglycanopathies often present with either limb-girdle muscular dystrophies
(LGMDs) or with congenital muscular dystrophies (CMDs) (Muntoni et al., 2008; Taniguchi-Ikeda
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et al., 2016). Central nervous system defects are sometimes present in dystroglycanopathy
patients with CMDs (Nickolls and Bönnemann, 2018); however, the role of alpha-DG
glycosylation in the peripheral nervous system in dystroglycanopathies is less understood.
Neuromuscular junction (NMJ) disruption has been reported in mouse models of
dystroglycanopathy (Côté et al., 1999; Herbst et al., 2009; Levedakou et al., 2005; Saito et al.,
2007). Additionally, alpha-DG glycosylation is necessary for NMJ formation in regenerating
skeletal muscle (Goddeeris et al., 2013). We recently found that zebrafish deficient for DG or
Fkrp exhibit NMJ defects during the late embryonic stages (Chapter 2). These data suggest that
DG glycosylation enzymes are essential for NMJ formation. Despite these findings, the timing
and mechanisms behind disrupted NMJ development remain unclear.
GMPPB-associated dystroglycanopathy is associated with phenotypes in both muscle
and NMJs. This condition results from mutations in GDP-Mannose Pyrophosphorylase B
(GMPPB), an enzyme that participates in DG glycosylation. GMPPB converts mannose-1phosphate to GDP-mannose, which is subsequently used in several glycosylation reactions such
as C-mannosylation and N-glycosylation (Carss et al., 2013). Patients with GMPPB-associated
dystroglycanopathy present with phenotypic variation. Similar to other dystroglycanopathies,
individuals with GMPPB mutations develop milder, adolescent- or adult-onset limb-girdle
muscular dystrophies or severe congenital muscular dystrophies with central nervous system
involvement (Bharucha-Goebel et al., 2015; Cabrera-Serrano et al., 2015; Carss et al., 2013;
Jensen et al., 2015; Oestergaard et al., 2016; Raphael et al., 2014). Although genotypephenotype correlations have emerged in regard to these phenotypes (Jensen et al., 2015), there
is still phenotypic variation within individuals with the same molecular GMPPB variants, even
within families (Bharucha-Goebel et al., 2015). For example, individuals with the common c.79
G>C mutation associated with limb-girdle muscular dystrophy may also develop congenital
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myasthenic syndrome (CMS) (Belaya et al., 2015; Luo et al., 2017; Rodríguez Cruz et al., 2016).
CMS is a neuromuscular disorder characterized by poor neuromuscular transmission at the NMJ
(Finsterer, 2019). The age of symptomatic onset in individuals with the c.79 G>C variant is highly
variable (Bharucha-Goebel et al., 2015; Montagnese et al., 2017). Cases of epilepsy (Astrea et
al., 2018; Raphael et al., 2014), one case of autism spectrum disorder (Astrea et al., 2018),
pseudometabolic myopathy (Panicucci et al., 2018), and rhabdomyolysis (Cabrera-Serrano et al.,
2015) have also been reported in individuals with GMPPB mutations. These clinical studies
suggest that the phenotypic diversity observed with these disorders may be a result of genetic
and/or environmental factors. The above studies also suggest the importance of studying neural
features associated with these disorders and indicate that it is critical to examine how muscle
phenotypes develop or change over the course of one’s illness.
Most of the research concerning GMPPB-associated dystroglycanopathy has been
clinical and does not address the biological mechanisms underlying this disorder. Animal model
studies regarding GMPPB are limited. Gmppb morphant zebrafish exhibit sarcolemmal damage,
MTJ abnormalities, bent tails, and hypoglycosylated alpha-DG (Carss et al., 2013). There are
currently no published genomic models for this disorder in mouse, zebrafish, Drosophila, or any
other model organism. Zebrafish offer many advantages for studying neuromuscular diseases
such as GMPPB-associated dystroglycanopathy. They are externally fertilized, possess high
fecundity and rapid development, and are transparent for the first several days of life (reviewed
by (Gibbs et al., 2013)). This allows for visualization of their muscle and/or nerves via
immunofluorescence microscopy. Recently, genome editing techniques such as TALENs and
CRISPR/Cas9 have made genomic manipulations more precise and accessible in zebrafish
(reviewed by (Cornet et al., 2018; Liu et al., 2019; Rafferty and Quinn, 2018; Simone et al.,
2018)). Zebrafish have been especially advantageous in elucidating the cell behaviors in the
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context of neuromuscular disorders, including muscle cell-ECM adhesion mechanisms. We
previously found that Nrk2b-mediated NAD+ production potentiates laminin organization at the
MTJ during zebrafish muscle development (Goody et al., 2010). We then determined that
exogenous NAD+ is sufficient to improve laminin organization, muscle structure, and function
two zebrafish models of dystroglycanopathy ((Goody et al., 2012), Chapter 2). However,
whether NAD+ remains beneficial for GMPPB-associated dystroglycanopathy has not been
investigated.
To address questions regarding cell-ECM adhesion and neuromuscular phenotypic
variation in GMPPB-associated dystroglycanopathy, we used CRISPR/Cas9 mutagenesis to
engineer a gmppb mutant zebrafish line. Programmed DNA was inserted near the 3’ end of
intron 2. RNA-seq analyses revealed the presence of multiple splice variants in gmppb mutants
that are predicted to result in premature stop codons. We determined that gmppb mutants
have abnormal beta-DG localization. Surprisingly, we found that NAD+ supplementation is not
sufficient to rescue muscle and MTJ phenotypes. Additionally, gmppb mutants exhibited
phenotypic variation, and “severe” embryos had wider MTJ angles and increased levels of
dystrophy compared to “mild” embryos. We detected defects in early primary motoneuron
development in gmppb mutants. Although gmppb mutants exhibited NMJ defects, these were
not significantly different between “mild” and “severe” gmppb mutants. We subsequently found
that gmppb mutants can be quantitatively separated into mild and severe phenotypes based on
birefringence image analysis at 2 dpf. Longitudinal experiments revealed that a portion of
gmppb mutants initially presenting with severe phenotypes recovered to milder phenotypes by
7 dpf. Taken together, these results suggest that gmppb mutants exhibit a degree of phenotypic
variability similar to that of humans and undergo phenotypic shifts throughout the first several
days of life.
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3.2. Results
3.2.1. Characterization of gmppb mutants
In humans, the most commonly reported GMPPB mutation is single-nucleotide
substitution associated with phenotypic variation: c.79 G>C (Bharucha-Goebel et al., 2015;
Cabrera-Serrano et al., 2015; Carss et al., 2013; Jensen et al., 2015; Montagnese et al., 2017;
Oestergaard et al., 2016; Raphael et al., 2014). To answer questions regarding cell-ECM
adhesion and phenotypic variation in the context of GMPPB-associated dystroglycanopathy, we
used CRISPR/Cas9 mutagenesis (Gagnon et al., 2014) to engineer a zebrafish gmppb mutant. A
preliminary RNA-seq experiment was performed on a pool of wild-type and gmppb mutants.
This experiment revealed that programmed DNA was inserted near the junction of intron 2 and
exon 3 of gmppb as expected (Appendix B). In addition to detecting correctly spliced gmppb
transcripts, we detected four alternative splice variants in the gmppb mutant samples (Fig. 3.1BC, Appendix B). At least three of these variants are predicted to result in premature stop codons
(Fig. 3.1A1, Appendix B). These data suggest that gmppb mutants are hypomorphic in nature.
The zebrafish gmppb morphant exhibits reduced body size, smaller eyes, and
disorganized muscle fibers that cross the myotome boundaries at 48 hpf (Carss et al., 2013). We
found that gmppb mutant embryos had abnormal tail morphology (Fig. 3.1F), as well as muscle
fibers spanning multiple myotomes (MTJ failure) and fiber detachment (Fig. 3.1G-G2, I-I1). These
data show that aberrant muscle phenotypes are present in this model, suggesting that gmppb
mutants an attractive model for studying cell-matrix adhesion in the context of GMPPBassociated dystroglycanopathy.
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Figure 3.1. Characterization of gmppb mutant zebrafish embryos. (A) Biochemical function of
GMPPB. Note that GMPPB synthesizes GDP-mannose from mannose-1-phosphate and this
product is used in several glycosylation reactions. Adapted from Carss et al. (2013). (A1)
Predicted location of the gmppb mutation relative to two common mutations in human
populations. Based on RNA-seq data, the gmppb mutation is predicted to introduce premature
stop codons in the nucleotidyl transferase domain of the protein due to alternative splicing.
Schematic adapted from Carss et al. (2013). (B-C) Proposed mechanisms of RNA splicing in wildtype (B) and mutant (C) embryos. The insertion of the stop cassette (blue) in intron 2-3 (yellow)
introduces alternative splice sites that generate alternative RNA transcripts. (D-E) Anterior left,
dorsal top, side-mounted 2 dpf wild-type embryos. (D-D1) Live brightfield (D) and birefringence
(D1) images of 2 dpf wild-type embryo. (E-E2) Wild-type embryo stained for f-actin (phalloidin,
gray). Note normal MTJ morphology (white arrow) and lack of fiber detachment. (F-G) Anterior
left, dorsal top, side-mounted 2 dpf gmppb mutant embryos. (F-F1) Live brightfield (F) and
birefringence (F1) images of 2 dpf gmppb mutants. Note abnormal posterior morphology (black
arrowhead). (G-G2) Mutant embryo stained for f-actin (phalloidin, gray). Note breaks in MTJ
(white arrowhead) and fiber detachment (red arrowhead) that are not present in the wild-type
embryo. (H-I1) Anterior left, dorsal top, side-mounted 3 dpf embryos stained for f-actin
(phalloidin, gray). (H-H1) Wild-type embryo. Note lack of fiber detachments or crossings. (I-I1)
gmppb mutant embryo. Note muscle fibers crossing the MTJ boundaries. Scalebars are 50
micrometers.
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3.2.2. NAD+ is not sufficient to improve muscle phenotypes in gmppb mutants
NAD+/EmergenC supplementation prior to muscle development is sufficient to improve
muscle phenotypes in both dag1 morphant (Goody et al., 2012) and fkrp morphant zebrafish
(Fig. 2.1). Given that exogenous NAD+ reduces muscle degeneration in both of these
circumstances and that gmppb mutants exhibit muscle and MTJ phenotypes, we hypothesized
that NAD+ would improve muscle phenotypes in gmppb mutant embryos. Surprisingly, NAD+
supplementation was not sufficient to significantly improve MTJ angles, MTJ failure, and
dystrophy in gmppb mutant embryos (Fig. 3.2A-E). Patients with GMPPB mutations exhibit
variability in sarcolemmal beta-DG accumulation (Bharucha-Goebel et al., 2015; CabreraSerrano et al., 2015; Jensen et al., 2015; Oestergaard et al., 2016) and sometimes present with
Western blot mobility shifts in beta-DG (Sarkozy et al., 2018). We asked if beta-DG localization
was disrupted in gmppb mutants and found that isolated myofibers exhibited mislocalized betaDG and abnormal clustering of beta-DG on the edges of the fibers (Fig. 3.2G-H1) compared to
WT embryos (Fig. 3.2F-F1). Additionally, gmppb mutant myofibers were more circular in shape
than wild-type myofibers (Fig. 3.2J). Our results suggest that beta-DG mislocalization occurs in
gmppb mutants.
3.2.3. Gmppb mutants exhibit phenotypic variation in muscle
Humans harboring GMPPB mutations exhibit a broad range of symptoms and severities,
even when individuals have identical genetic variants (Belaya et al., 2015; Cabrera-Serrano et al.,
2015; Luo et al., 2017). Gmppb mutant zebrafish are an ideal model to address questions
regarding neuromuscular phenotypic variation. We imaged 72 hpf wild-type and gmppb mutant
embryos labeled for f-actin (phalloidin) to quantify MTJ angles, MTJ failure, and dystrophy at
this stage. We determined that compared to wild-type embryos (Fig. 3.3A), gmppb mutants
exhibit differences overall in terms of muscle (Fig. 3.3B, C). Additionally, we observed
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Figure 3.2. Gmppb mutants are not rescued by NAD+ supplementation and have abnormal
beta-DG localization. (A-B1) Anterior left, dorsal top, side-mounted embryos stained for f-actin
(phalloidin, gray). (A-A1) 72 hpf gmppb mutant. Note fiber detachment in the myotome (white
arrowhead). (B-B1) 72 hpf gmppb mutant treated with 0.1 mM NAD+ at 6 hpf. Note the muscle
fibers spanning multiple myotomes (yellow arrowhead). (C) MTJ angles are significantly
increased in gmppb mutant embryos (n=107 MTJs) compared to untreated (n=49 MTJs) and
NAD+-treated (n=58 MTJs) wild-type embryos. MTJ angles are not significantly reduced in NAD+treated gmppb mutants (n=84 MTJs) compared to untreated mutants. (D) There is not a
significant difference in MTJ failure between gmppb mutants treated with NAD+ (n=19 embryos)
and untreated gmppb mutants (n=19 embryos). (E) There is no significant difference in the
percent of myotomes with degeneration between gmppb mutants treated with (n=19 embryos)
and without (n=19 embryos) NAD+. (F-H1) Individual myofibers purified from 48 hpf embryos
stained for phalloidin (lettered panels, gray) and beta-DG (numbered panels, blue). (F-F1)
Control myofiber. Note that beta-DG localizes to the terminal edges of the myofibers (white
arrowhead). (G-H1) Gmppb mutant myofibers. Note how beta-DG is aggregated along the
myofibers (yellow arrowhead) and does not localize to the terminal ends. (I) There is no
significant difference in myofiber area between control (n=16 myofibers) and gmppb mutant
(n=38 myofibers) myofibers. (J) Myofiber shape was quantified in control (n=16 myofibers) and
gmppb mutant myofibers (n=38 myofibers) using the filament index. This metric quantifies how
much an object deviates from a circular shape: a lower filament index corresponds with a more
circular shape (Snow et al., 2008b). There is a significant reduction in the filament index in
gmppb mutants compared with controls. This suggests that gmppb mutant myofibers are more
circular. Myofiber scalebars are 10 micrometers, other scalebars are 50 micrometers, *p<0.05,
**p<0.01, ***p<0.001, ns non-significant.
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phenotypic variation within gmppb mutants, with embryos appearing “mild” or “severe” (Fig.
3.3B, C, Chapter 5, Section 5.10.2). Prior to staining our embryos, we performed a motility assay
and found that “severe” and “mild” gmppb mutants did not have statistically significant
differences in motility (Fig. 3.3D). We quantified MTJ angles, MTJ failure, and levels of dystrophy
in “mild” and “severe” gmppb mutants. “Severe” mutants had significantly worse MTJ angles
and increased levels of dystrophy compared to “mild” gmppb mutants (Fig. 3.3E, G). Although
we observed a trend in increased MTJ failure that correlated with phenotypic severity, this trend
was not significantly different between either class of mutant or wild-type embryos (Fig. 3.3F,
p=0.07 for wild-type and “severe” mutants). Taken together, these data suggest gmppb mutants
exhibit phenotypic variation in muscle.
3.2.4. Gmppb mutants exhibit neural phenotypes
Neuromuscular junction (NMJ) development requires tight coordination between both
motoneurons and muscle cells. Congenital myasthenic syndromes that affect the NMJ have
been documented in a number of patients with GMPPB-associated dystroglycanopathy (Belaya
et al., 2015; Luo et al., 2017; Rodríguez Cruz et al., 2016). We asked if motor axon pathfinding
and initial NMJ development are disrupted in gmppb mutants and if “mild” and “severe”
embryos exhibit differences in NMJ morphology. We found that CaP (ventral) primary motor
axon development was disrupted in 24 hpf gmppb mutant embryos compared to wild-type
embryos (Fig. 3.4A-C). A lower percentage of primary motor axons exited the spinal cord (Fig.
3.4D) and extended past the choice point (Fig. 3.4F) in gmppb mutants compared to controls.
However, we did not observe any significant differences in the axon length to the choice point
(Fig. 3.4E) or the length of the axons that extend beyond the choice point (Fig. 3.4G) between
either group. These data suggest that initial motoneuron development is disrupted in gmppb
mutants.
68

Figure 3.3. Gmppb mutants exhibit phenotypic variation in muscle. (A-C) Anterior left, dorsal
top, side-mounted 72 hpf embryos stained for f-actin (phalloidin, gray). (A) Control embryo. (B)
“Mild” gmppb mutant embryo. Note subtle fiber degeneration within the myotome (yellow
arrowhead) and wider MTJs. (C) “Severe” gmppb mutant embryo. Note abnormal myotome
shape (white arrowhead), fiber disorganization, and wider MTJs. (D) Motility in 72 hpf “severe”
gmppb mutant (n=8 embryos) embryos is significantly worsened compared to wild-type (n=12
embryos) embryos. However, there are no significant differences in motility between “mild”
mutants (n=21 embryos) and “severe” mutants. (E) “Severe” gmppb mutants (n=8 embryos)
exhibit significantly increased MTJ angles compared to “mild” gmppb mutants (n=21 embryos)
and wild-type (n=12 embryos). (F) MTJ failure is not significantly between wild-type (n=12
embryos), “mild” gmppb mutant (n=21 embryos), or “severe” gmppb mutant (n=8 embryos)
embryos (p=0.07 between wild-type and “severe” gmppb mutants). (G) “Severe” gmppb
mutants (n=8 embryos) exhibit a significantly greater percentage of myotomes with
degeneration than wild-type (n=12 embryos) or “mild” gmppb mutant (n=21 embryos) embryos.
Scalebars are 50 micrometers. *p<0.05, **p<0.01, ***p<0.001, ns = non-significant.
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We next asked if NMJ formation was disrupted in gmppb mutants and if mutants
exhibited variation in NMJ morphology. We analyzed NMJ structure at 72 hpf by staining for
presynaptic synaptic vesicle protein (SV2) and postsynaptic acetylcholine receptors (alphabungarotoxin), focusing on innervation of fast-twitch fibers (distributed innervation, Fig. 3.4).
Despite disruptions in initial motor axon development, gmppb embryos still formed synapses
(Fig. 3.4I-J4). In contrast to wild-type embryos, gmppb “mild” and “severe” mutants exhibited
reduced distributed innervation within the myotome (Fig. 3.4H-J4). We used a semi-automated
MATLAB protocol (Chapter 5, Section 5.10.8) to quantify the degree of distributed innervation.
We found that skeleton length was reduced in both classes of gmppb mutants compared to
wild-type embryos; however, there were no significant differences between “mild” and “severe”
gmppb embryos. On average, “mild” gmppb mutant skeleton length was 49.2% of that of the
wild-type, and “severe” gmppb mutant skeleton length was 49.1% that of the wild-type (Fig.
3.4K). Taken together these results suggest that although NMJ morphology is disrupted in
gmppb mutants, NMJs are not significantly different between “mild” and “severe” mutants.
3.2.5 Gmppb mutants can be quantitatively separated into mild and severe phenotypes
The above data suggest that gmppb mutants have “mild” and “severe” phenotypes that
exhibit significant differences in terms of fiber degeneration and MTJ angles. However, it is key
to classify the phenotypic severity of gmppb mutants with a non-biased approach. To achieve
this, we captured birefringence images of wild-type and gmppb mutant embryos at 2 dpf and
calculated the percent area and percent mean gray value (MGV) (Berger et al., 2012) relative to
wild-type embryos at this stage. We found that gmppb mutants can be quantitatively separated
into mild and severe phenotypes (Fig. 3.5) based on their percent area of birefringence

70

Figure 3.4. Gmppb mutants exhibit neural phenotypes. (A-C1) Anterior left, dorsal-top sidemounted 24 hpf embryos stained for znp-1 (white) labeling primary motoneurons. (A-A1) Wildtype embryos. Note how primary motor axons extend past the choice point (white arrow). (BB1) gmppb mutant embryos predicted to be “mild”. Some primary motor axons are truncated
and do not extend past the choice point (yellow arrowhead). (C-C1) gmppb mutant embryos
predicted to be “severe”. Note that many motor axons are truncated. (D) A significantly lower
percentage of 24 hpf gmppb mutant motor axons (n=29 embryos) exit the spinal compared to
wild-type (n=27 embryos) embryos. (E) Axon length to the choice point is not significantly
different between 24 hpf wild-type (n=93 axons) and gmppb mutant (n= 115 axons) embryos. (F)
The percent of axons that extend past the choice point is significantly lower in 24 hpf gmppb
mutant (n=15 embryos) than in wild-type (n=13 embryos) embryos. (G) The length of axons that
extend past the choice point does not significantly differ between wild-type (n=45 axons) and
gmppb mutant (n=21 axons) embryos. (H-J4) Anterior left, dorsal top, side-mounted embryos
labeled with acetylcholine receptors (AChRs) and synaptic vesicle protein 2 (SV2). (Lettered
panels) Merged channels of AChR and SV2. (1) Skeletonized images. (2) Magnification of AChR
channel. (3) Magnification of SV2 channel. (4) Magnification of skeletonized image. (H-H4)
Control embryo. (I-I4) “Mild” gmppb mutant embryo exhibiting a reduced degree of distributed
innervation within the myotome. (J-J4) “Severe” gmppb mutant embryo exhibiting reduced
distributed innervation within the myotome. (K) Percent of wild-type skeleton length per muscle
segment in wild-type (n=72 half-myotomes) and gmppb mutant (“mild” n=78 half-myotomes;
“severe” n=106 half-myotomes) embryos. These percentages are significantly lower in both
classes of gmppb mutants compared to wild-type but are not significantly different between
either class of mutants. Scalebars are 50 micrometers. Error bars in (K) are standard error of the
mean (L). *p<0.05, **p<0.01, ***p<0.001, ns= non-significant.
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(Fig. 3.5D) and percent MGV (Fig. 3.5E). In mild gmppb mutants, both of these values were 85%
or higher (see Chapter 5, Section 5.10.2). These results suggest that in terms of muscle, gmppb
mutants exhibit phenotypic variation that is similar to the variability that is in patients with
GMPPB-associated dystroglycanopathy.
3.2.6. A portion of severe gmppb mutants recover to milder phenotypes
Gmppb mutant embryos exhibit phenotypic variation in terms of muscle degeneration
and MTJ angles (Fig. 3.3E, G) and can be quantitatively separated into mild and severe
phenotypes based on birefringence image analysis at 2 dpf (Fig. 3.5). As this variation is
detectable at an early stage in life, we asked if such variation in gmppb mutants persists into the
early larval stages. We performed longitudinal birefringence assays and analyzed birefringence
images of wild-type and gmppb mutant zebrafish at 2 dpf and 7 dpf (Fig. 3.6A-D4). Surprisingly,
by 7 dpf, a portion of gmppb mutants that initially had severe phenotypes presented with mild
phenotypes (Fig. 3.6C-C4, F-I). The average percent area in severe-mild gmppb mutants
increased to levels similar to those of mild gmppb mutant and wild-type zebrafish at 7 dpf (Fig.
3.6H). Between 2 dpf and 7 dpf, the average severe-mild gmppb mutant percent MGV
increased, whereas the average percent MGV of gmppb mutants that remained severe
decreased (Fig. 3.6I). The reverse of this was rare: we only observed two embryos/larvae that
had a mild phenotype at 2 dpf that were severe at 7 dpf (one embryo/larva was just under the
threshold, data not shown). Taken together, these results suggest that gmppb mutants exhibit
phenotypic plasticity throughout the first several days of life.
3.3. Discussion
Individuals with GMPPB-associated dystroglycanopathy present with a broad range of
symptoms that vary in terms of age of onset, severity, and involvement of the nervous system. A
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Figure 3.5. Gmppb mutants can be quantitatively separated into mild and severe phenotypes
at 2 dpf. (A-C1) Anterior left, dorsal top, side-mounted 2 dpf embryos imaged live for brightfield
(lettered panels) and birefringence (numbered panels). (A-A1) Control embryo. (B-B1) Mild
gmppb mutant embryo. Note abnormal tail morphology (black arrowhead). (C-C1) Severe
gmppb mutant embryo. Note abnormal tail morphology (black and white arrowheads) and
segments with reduced brightness. (D) Quantification of the percent area of birefringence for 2
dpf control (n=71 embryos), mild, (n=50 embryos) and severe (n=60 embryos) gmppb embryos.
There is not a significant difference in the percent area of birefringence between controls and
mild gmppb mutants. Severe gmppb mutant embryos have a significant reduction in the percent
area of birefringence compared with mild gmppb mutants and control embryos. (E)
Quantification of percent mean gray value (MGV) for 2 dpf wild-type (n=71 embryos), mild
(n=50 embryos), and severe (n=60 embryos) gmppb embryos. Severe gmppb mutant embryos
have a significant reduction in the percent MGV compared with mild gmppb mutants and
controls. *p<0.05, **p<0.01, ***p<0.001, ns= non-significant.
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major gap in our understanding of GMPPB-associated disorders is how one mutated GMPPB
allele can result in multiple phenotypes. Using CRISPR/Cas9 mutagenesis, we designed a gmppb
mutant zebrafish line to investigate the mechanisms underlying phenotypic variation in GMPPBassociated dystroglycanopathy. To our knowledge, this is the first animal model of this condition
that has been engineered at the genomic level. In contrast to previous studies in our lab
regarding NAD+ and dystroglycanopathy, NAD+ supplementation failed to rescue gmppb
mutants. We found that 72 hpf gmppb mutants exhibit phenotypic variation. Specifically, we
showed that embryos appearing more severe had significant differences in MTJ angles and fiber
degeneration compared to milder embryos. We uncovered a novel defect in motor axon
development in 24 hpf gmppb mutants. Although we detected NMJ abnormalities in gmppb
mutants, these were not significantly variable between “mild” and “severe” mutants. At 2 dpf,
we detected mild and severe gmppb mutant phenotypes based on birefringence image analysis.
Longitudinal studies revealed that gmppb mutants exhibited phenotypic plasticity. Our data
indicate that zebrafish gmppb mutants exhibit a spectrum of phenotypic variation similar to that
of human populations. This suggests that gmppb mutant zebrafish are a suitable model for
studying the mechanisms underlying phenotypic variation in GMPPB-associated
dystroglycanopathy.
3.3.1. Alternative splicing in gmppb mutants
Gmppb morphant zebrafish have been superficially characterized at 48 hpf and possess
abnormal muscle structure, curved tails, motility defects, smaller body size, and smaller eyes
(Carss et al., 2013). There are currently no other published animal models of GMPPB-associated
dystroglycanopathy. Here, we showed that gmppb mutant zebrafish engineered via CRISPR/Cas9
mutagenesis exhibit abnormal tail morphology, as well as MTJ failure and muscle degeneration
(Fig. 3.1). Preliminary RNA-seq analysis revealed that gmppb mutants have an insertion near the
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Figure 3.6. A portion of severe gmppb mutants recover to mild phenotypes by 7 dpf. (A1-D4)
Anterior left, dorsal top, side-mounted embryos and larvae live-imaged for brightfield (1-2) and
birefringence (3-4) at 2 dpf (odd panels) and 7 dpf (even panels). (A1-A4) Control embryo/larva.
(B1-B4) Mild gmppb mutant embryo/larva. (C1-C4) Severe-mild gmppb mutant embryo/larva.
(D1-D4) Severe gmppb mutant embryo/larva. Note abnormal posterior morphology (white
arrowhead) in 7 dpf larva. (E) Legend for (F-I) graphs for control (black), mild (dark blue), severemild (teal) and severe (light blue) larvae. (F) Quantification of percent area of birefringence
between control (n=51 larvae), mild (n=28 larvae), severe-mild (n=15 larvae), and severe (n=18
larvae) larvae at 7 dpf. Percent area is significantly lower in severe larvae compared to all other
groups. (G) Quantification of percent mean gray value (MGV) between control (n=51 larvae),
mild (n=28 larvae), severe-mild (n=15 larvae), and severe (n=18 larvae) larvae at 7 dpf. Severe
larvae have a significant reduction in percent MGV compared to all other groups. (H) Average
percent area of birefringence between control, mild, severe-mild, and severe larvae at 2 dpf and
7 dpf. Severe-mild gmppb mutant percent area is above 85% at 7 dpf, whereas severe gmppb
mutant percent area remains below 85% on average. (I) Average percent MGV between control,
mild, severe-mild, and severe embryos at 2 dpf and 7 dpf. Severe-mild gmppb mutant percent
MGV is higher at 7 dpf than at 2 dpf, whereas severe gmppb mutant percent MGV is lower at 7
dpf than at 2 dpf on average. Since data are only shown for 2 dpf and 7 dpf, a linear relationship
should not be assumed for the data presented in (H) and (I). Error bars in (H) and (I) are
standard error of the mean, *p<0.05, **p<0.01, ***p<0.001, ns= non-significant.
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end of intron 2 and have mis-spliced gmppb transcripts in addition to correctly spliced
transcripts. Four classes of mis-spliced variants were detected (Appendix B). Three of these
variants have been predicted to shift the reading frame and result in premature stop codons in
the protein sequence (Fig. 3.1, Appendix B). This hypomorphic mutant is well-suited to study the
basic biological mechanisms in the context of GMPPB-associated dystroglycanopathy.
Gmppb mutant zebrafish exhibiting RNA mis-splicing are just one example of alternative
splicing in the context of neuromuscular disease. Alternative RNA splicing has been reported in
the context of MDC1A (Kemaladewi et al., 2017; Sunada et al., 1995), Fukuyama Congenital
Muscular Dystrophy (Taniguchi-Ikeda et al., 2011), molecular variants of Duchenne and Becker
Muscular Dystrophies (Béroud et al., 2004; Takeshima et al., 2010; Todeschini et al., 2016) and
Limb-Girdle Muscular Dystrophy Type 1B (LGMD1B) (Ito et al., 2017; Luo et al., 2014) (reviewed
by (Montes et al., 2019; Scotti and Swanson, 2016)). LGMD1B is associated with LMNA
mutations. Depending on the molecular basis of the LMNA mutation, individuals can also
develop other conditions, including Emery-Dreifuss Muscular Dystrophy (EDMD), progeria
syndromes, and lipodystrophy (Scotti and Swanson, 2016). Gmppb mutants have multiple
classes of incorrectly spliced gmppb reads and exhibit phenotypic variation; thus, it would be
interesting to determine whether different phenotypic classes of gmppb mutants have different
mis-spliced gmppb reads.
3.3.2 Cell-matrix adhesion and GMPPB-associated dystroglycanopathy
Muscle fibers must adhere to the myotendinous junction (MTJ) for proper development
and homeostasis. We previously identified a pathway that contributes to this process and
determined that Nrk2b-mediated NAD+ synthesis drives laminin organization at the MTJ during
zebrafish muscle development (Goody et al., 2010). We subsequently showed that NAD+
supplementation is sufficient to improve laminin organization, muscle structure, and muscle
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function in the absence of either DG or Itga7 (Goody et al., 2012), or in the absence of Fkrp
(Chapter 2). Based on this information, we hypothesized that NAD+ would be sufficient to
improve muscle structure in gmppb mutants. Surprisingly, we found that NAD+ supplementation
prior to muscle development is not sufficient to improve muscle in gmppb mutant embryos. We
subsequently found that beta-DG fails to localize to the terminal ends of individual gmppb
mutant muscle fibers and is mislocalized along the myofibers.
DG clustering is highly variable among patients with GMPPB-associated
dystroglycanopathy (Bharucha-Goebel et al., 2015; Cabrera-Serrano et al., 2015; Jensen et al.,
2015; Oestergaard et al., 2016). A recent study has suggested that beta-DG may also be a
marker of disease and determined that the mobility of beta-DG shifts on Western blots
analyzing this protein in a subset of patients with GMPPB-associated dystroglycanopathy and
that GMPPB is required for N-linked glycosylation of beta-DG (Sarkozy et al., 2018). This is not
surprising, given that beta-DG contains 1 N-linked glycosylation site (Barresi and Campbell,
2006). N-glycans are also found on all integrin heterodimers (Janik et al., 2010) and cleavage of
N-linked glycans on Integrinalpha5beta1 prevents its binding to fibronectin in the ECM (Zheng et
al., 1994). It is currently unknown whether N-glycosylation of integrins promotes either laminin
binding affinity or membrane localization of Integrinalpha6beta1 or Integrinalpha7beta1.
Determining whether GMPPB and/or N-glycosylation are necessary for either of these processes
to occur would be an interesting avenue to explore in the future.
3.3.3. Primary motoneuron disruption in GMPPB-associated dystroglycanopathy
Dystroglycan (DG) is associated with the NMJ through the utrophin glycoprotein
complex (Deconinck et al., 1997). Thus, it is not surprising that NMJ morphology is disrupted in
dystroglycanopathies. Fukutin- and Large- deficient mice have abnormal NMJs shortly after birth
(Herbst et al., 2009; Saito et al., 2007). In Chapter 2, we show that NMJ development is
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disrupted in fkrp morphants at 3 dpf (Fig. 2.5, 2.6). Congenital myasthenic syndrome, a disease
that affects neuromuscular transmission at the NMJ, has been documented in patients with
GMPPB-associated dystroglycanopathy (Belaya et al., 2015; Luo et al., 2017; Rodríguez Cruz et
al., 2016). However, it is unclear when exactly NMJ development becomes disrupted. Early in
development, primary motoneurons exit the spinal cord and innervate myotomes (Panzer et al.,
2005). Here, we showed that primary motoneuron development is disrupted in gmppb mutant
zebrafish at 24 hpf. To our knowledge, we are the first to report this in the context of
dystroglycanopathy. Several ECM proteins implicated in various stages of motoneuron
development are glycosylated, including plexin3A, collagen XV, collagen XIII, and sema5a
(Feldner et al., 2007; Guillon et al., 2016; Hilario et al., 2009; Schneider and Granato, 2006).
Therefore, it is possible that some of these ECM components have altered glycosylation and/or
function in gmppb mutants. We found that a lower percentage of motor axons exit the spinal
cord in gmppb mutants (Fig. 3.4D). We hypothesize that impaired glycosylation of one or more
of the aforementioned guidance proteins could inhibit motor axon growth in gmppb mutants.
Specifically, we would test whether expression and/or localization of any of these guidance
proteins are altered in gmppb mutant embryos and if levels of abnormal expression and/or
localization correlate with mild and severe phenotypes detected via birefringence.
Although early motoneuron defects and disrupted NMJ morphology are present, we
also showed that synapses still form in gmppb mutants (Fig. 3.4H-J). Although NMJ morphology
was disrupted in gmppb mutants, we did not detect any significant differences in skeleton
length between “ mild” and “severe” gmppb mutant embryos. These results were somewhat
surprising, given the range of variability we observed in primary motor axon phenotypes in
gmppb mutants (Fig. 3.4). In the future, it will be interesting to determine if NMJ formation in
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gmppb mutants is facilitated by recovery of primary motor axon pathfinding, compensatory
secondary axon pathfinding, or cycles of regeneration following degeneration.
3.3.4. Phenotypic variation and plasticity in gmppb mutants
Phenotypic variation is common in neuromuscular diseases, including GMPPBassociated dystroglycanopathy. Although genotype-phenotype correlations are starting to
emerge, individuals still present with a broad spectrum of symptoms and severities. This is
especially true for the c.79 G>C variant associated with Limb-Girdle Muscular Dystrophy Type 2T
(LGMD2T) and Congenital Myasthenic Syndrome. Individuals with this specific mutation have
highly variable symptoms and ages of onset (Bharucha-Goebel et al., 2015; Cabrera-Serrano et
al., 2015; Carss et al., 2013; Jensen et al., 2015; Montagnese et al., 2017; Oestergaard et al.,
2016; Raphael et al., 2014). We currently do not understand how individuals with the same
mutant allele can experience drastically different symptoms and severities. Gmppb mutants
exhibited a similar degree of phenotypic variation. These embryos can be categorized into mild
and severe phenotypes based on birefringence image analysis at 2 dpf. By 7 dpf, a portion of
gmppb mutants initially presenting with severe phenotypes recovered to milder phenotypes.
Conversely, we only observed two gmppb mutants initially presenting as mild that became
severe by 7 dpf (one was just under the threshold). Our data do not resolve the mechanisms
underlying phenotypic variation and plasticity in this model. We hypothesize that this
phenotypic variation is driven by one or more distinct molecular and/or cellular mechanisms.
Several potential mechanisms include differences in RNA mis-splicing, muscle regeneration
and/or degeneration, motor axon pathfinding, and cell adhesion strength (detailed in Chapter
4). These future studies aim to provide insight regarding the cell behaviors underlying
phenotypic variation and plasticity in gmppb mutants.
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3.4. Conclusion
Phenotypic variation is common in many neuromuscular disorders, including the
dystroglycanopathies. We took advantage of CRISPR/Cas9 technology to engineer a zebrafish
model of GMPPB-associated dystroglycanopathy, a neuromuscular disorder with highly variable
clinical presentation. We found that the gmppb mutant allele is hypomorphic and mutants
present with alternatively spliced gmppb RNA reads. Gmppb mutants also exhibited abnormal
muscle and MTJ structure. In contrast to previous studies concerning other zebrafish models of
dystroglycanopathies, these attributes are not improved with NAD+ supplementation prior to
muscle development. We found that at 72 hpf, gmppb mutants exhibited “mild” and “severe”
phenotypes, particularly in regard to muscle degeneration and MTJ angles. Although
motoneuron development and NMJ morphology were abnormal in gmppb mutants, we did not
find significant differences in NMJ morphology between “mild” and “severe” gmppb mutants.
We determined that gmppb mutants can be quantitatively separated into mild and severe
phenotypes at 2 dpf. Longitudinal birefringence imaging revealed that a portion of gmppb
mutants initially presenting with severe phenotypes presented with milder phenotypes by 7 dpf.
Taken together, our data indicate that gmppb mutants are well-suited to study the molecular
and cellular behaviors underlying phenotypic variation in dystroglycanopathies.
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CHAPTER 4
FUTURE DIRECTIONS
4.1. Introduction
The journey to elucidating the developmental and cellular behaviors evident in
dystroglycanopathies is far from complete. While the work described herein has provided
valuable insight regarding neuromuscular development and phenotypic variation in these
conditions, it has also led to new and important questions. This chapter provides examples of
exciting future directions to explore regarding zebrafish models of dystroglycanopathy. The
following experiments are only a microcosm of possibilities. Other potential areas of exploration
that will not be discussed in this chapter include the design of humanized gmppb mutant
zebrafish, determining whether ECM proteins that participate in motoneuron guidance are
impaired in gmppb mutants, elucidating intrinsic compensatory mechanisms present in gmppb
mutants, and longitudinal studies of zebrafish models of FKRP-associated dystroglycanopathy. It
is important to note that our preliminary experiments analyzing muscle and NMJs should be
repeated with gmppb mutants that have been classified as mild or severe via birefringence
analysis and should be repeated with a larger sample size. It is also essential to determine the
exact molecular basis of gmppb mutants, particularly the genomic DNA sequence of intron 2.
4.2. New zebrafish models of FKRP-associated dystroglycanopathy
Zebrafish embryos have been advantageous in determining the cellular and molecular
mechanisms governing disease phenotypes in muscular dystrophies, including
dystroglycanopathies. While fkrp morphants are a respectable model for exploring FKRPassociated dystroglycanopathy, it would be useful to leverage novel fkrp mutant zebrafish in
future research projects. Repeating experiments described in Chapter 2, especially NAD+,
laminin, and NMJ experiments, with fkrp mutant zebrafish is ideal in order to confirm that our
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observations also occur in fkrp mutants. Second, these models would be important for
performing any longitudinal studies regarding FKRP-associated dystroglycanopathy in zebrafish,
as the efficacy of morpholinos fades by 5 dpf.
Our lab has recently obtained two fkrp mutant zebrafish models (kind gifts from Dr.
James Dowling and Dr. Matthew Alexander). One of these mutants is listed in the Sanger
database contains a single nucleotide substitution which results in a premature stop codon at
amino acid 169 (Kettleborough et al., 2013) but remains uncharacterized. The additional model
we obtained contains a 13 bp deletion generated by TALENs and also carriers a heat-shock
inducible promoter for human FKRP carrying the L276I mutation (Serafini et al., 2018). When
heat-shocked, this line exhibits a milder phenotype (Serafini et al., 2018). These mutant lines
would be ideal to use for future studies regarding FKRP-associated dystroglycanopathy.
4.3. What are the tissue-specific requirements of Fkrp?
In Chapter 2, we determined that muscle-specific overexpression of Fkrp improved MTJ
morphology; however, it was not sufficient to improve fiber resiliency and mobility in fkrp
morphant zebrafish. Given that previous studies demonstrated that this enzyme resides in the
perinucleus, sarcolemma, and Golgi cisternae (Alhamidi et al., 2011) and that muscle-specific
expression of LARGE improves muscle pathology in large mutant mice (Gumerson et al., 2013),
these results are surprising and intriguing. Our work is the first to indicate that Fkrp is required
outside of muscle fibers for normal muscle development and homeostasis.
We also showed that Fkrp in zebrafish is required for homeostasis of two specialized
muscle junctions that are necessary for proper muscle function: the myotendinous junction
(MTJ) and the neuromuscular junction (NMJ). These interfaces link muscle with tendons and
motoneurons, respectively. We speculate that Fkrp activity may be required in tendons and/or
motoneurons, either independently or concurrently with activity in muscle, for proper MTJ and
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neuromuscular development. Experiments that take advantage of additional tissue-specific
promoters are an important first step in determining the tissue-specific requirements of Fkrp.
We would drive Fkrp expression under motoneuron-specific promoters such as mnx:1 (primary
motoneurons) (Zelenchuk and Brusés, 2011) or gata2 (secondary motoneurons) (Meng et al.,
1997) and a tenocyte-specific promoter such as scxa (Chen and Galloway, 2014) and perform
experiments with transgenics similar to those described in Chapter 2. These promoters would be
fused to non-GFP fluorophores such as mCherry or mKate in order to create double transgenics
in which Fkrp is overexpressed simultaneously in multiple tissues. If any of these combinations
of tissue-specific overexpression rescued mobility or fiber degeneration in fkrp morphants or
mutants, it would suggest that Fkrp is sufficient in those tissues for proper muscle development
and homeostasis. Generating tissue-specific fkrp mutants to determine where Fkrp is necessary
for proper muscle development and homeostasis is another possible avenue to explore.
Experiments that elucidate the tissue-specific roles of Fkrp are key for providing insight for
clinical researchers considering gene therapy as an avenue for improving muscle disease in
patients with FKRP-associated dystroglycanopathy.
4.4. Functional rescue of gmppb mutants
When a novel genetic mutant is generated with a clear phenotype, it is important to
determine if that mutant can be improved via mRNA rescue or chemical interventions. Injection
of mRNA constructs designed to induce overexpression of Gmppb is one approach. Several
transgenic gateway constructs designed for this purpose are currently under construction. These
include Tg(bact2:gmppb-EGFP) and Tg(hsp70l:gmppb-EGFP). These vectors can be injected into
1-cell stage gmppb mutant embryos. We would expect Tg(bact2:gmppb-EGFP) embryos to
constitutively express Gmppb-EGFP without the need for additional manipulation.
Tg(hsp70l:gmppb-EGFP) embryos would require heat shock at 38°C for 2 hours during an early
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developmental stage (likely 15 somites or earlier, see Chapter 2) to induce Gmppb-EGFP
expression. Successfully injected embryos would be raised to adulthood, and transgenic F1
progeny will be used for subsequent experiments. One outcome is that Gmppb-EGFP expressing
embryos would exhibit improved muscle phenotypes. However, this approach might not rescue
gmppb mutant phenotypes because our gmppb mutants are splice mutants.
An alternative method for rescuing gmppb mutants is to supplement embryos with
exogenous GDP-mannose. Previous studies demonstrated that mannose supplementation
improved phenotypes in cultured fibroblasts from individuals with congenital disorders of
glycosylation (Rush et al., 2000). GMPPB synthesizes GDP-mannose from mannose-1-phosphate
(Fig. 3.1A; (Carss et al., 2013)); therefore, we hypothesize that exogenous GDP-mannose can
restore functional glycosylation to gmppb mutants. We would supplement gmppb mutants at
several developmental stages with GDP-mannose in a manner similar to NAD+ supplementation.
Designing experiments this way would allow us to determine if GDP-mannose supplementation
is necessary prior to muscle development in gmppb mutants. Additionally, it would be
interesting carry out these experiments longitudinally to determine if GDP-mannose repletion
after muscle development gradually improves phenotypes in gmppb mutations. If GDP-mannose
repletion experiments successfully rescued gmppb mutants, these results would have
translational implications as a potential therapeutic for patients with GMPPB-associated
dystroglycanopathy.
4.5. Elucidating the mechanisms underlying phenotypic variation in gmppb mutants
In Chapter 3, we showed that gmppb mutant zebrafish exhibit phenotypic variation.
Gmppb mutants presenting with more “severe” phenotypes (not classified by birefringence
image analysis) on average exhibited greater degrees of muscle degeneration. We also found
that primary motor axon pathfinding was disrupted in gmppb mutants at 1 dpf (Fig. 3.4A-C). We
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determined that gmppb mutants can be quantitatively classified as mild or severe based on
birefringence image analysis at 2 dpf (Fig. 3.5) and that a portion of gmppb mutants initially
presenting with severe phenotypes recover to mild phenotypes by 7 dpf (Fig. 3.6). These results
beget the question of how these phenotypes, and their variability, originate in gmppb mutants.
Such variation could occur via several mechanisms at the molecular and cellular levels (Fig. 4.1)
and will be discussed in the following subsections.
4.5.1. Do levels of RNA mis-splicing correlate between mild and severe gmppb mutant
phenotypes?
The gmppb mutant zebrafish described in Chapter 3 have an insertion in intron 2 that
leads to alternative RNA splicing. These variants are predicted to generate truncated protein
products based on the location of the open reading frame (Fig. 3.1A, Appendix B). In Chapter 3,
we revealed that gmppb mutant zebrafish exhibit mild and severe phenotypes and that a
portion of mutants initially presenting as severe recover to mild. Although there are likely cell
behaviors that accompany these observations, it is also critical that we consider the role that
alternative splicing levels could play in phenotypic variation and plasticity.
A collaborative study between the labs of Dr. Clarissa Henry and Dr. Benjamin King at
the University of Maine is currently underway to answer this question. Longitudinal
birefringence imaging was performed on control and gmppb mutant embryos at 2 dpf, 4 dpf,
and 7 dpf, and birefringence images were analyzed immediately after each time point.
Representative control, gmppb mild, and gmppb severe embryos at 4 dpf and 7 dpf were pooled
together for deep sequencing (RNA-Seq). Data analysis of the deep sequencing data is currently
in progress. When complete, this study is expected to determine whether levels of incorrectly
spliced gmppb RNA correlate with mild and severe phenotypes (Fig. 4.1A). Another potential
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Figure 4.1. Potential mechanisms underlying phenotypic variation in gmppb mutant zebrafish.
(A) One possible mechanism of phenotypic variation is different levels of RNA mis-splicing of the
GMPPB transcript between mild and severe mutants. We hypothesize that severe gmppb
mutants would exhibit higher levels of RNA mis-splicing. (B) It is also possible that mild and
severe gmppb mutants have differences in regenerative capacity of their muscle. Our hypothesis
is that severe gmppb mutants experience more muscle degeneration (red arrowhead) than mild
gmppb mutants (green arrowhead) and that mild gmppb mutants could regenerate muscle. (C)
We must also consider the possibility that the severity of primary motor axon pathfinding
predicts phenotypic severity in the muscle of gmppb mutants. We hypothesize that severe
gmppb mutants exhibit more severe disruptions of motor axon pathfinding early in
development. (D) An additional mechanism to test is whether mild and severe gmppb mutants
have differences in cell adhesion strength. We hypothesize that mild mutants will have greater
cell adhesion and fiber resiliency and will be less prone to muscle wasting upon
electrostimulation.
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Figure 4.1.
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outcome of this study is that different gmppb RNA splice variants correspond with different
phenotypic classes of gmppb mutants.
4.5.2. Examining differences in muscle regeneration in gmppb mutants
In Chapter 3, we found that gmppb mutant zebrafish exhibit mild and severe
phenotypes based on birefringence image analysis at 2 dpf (Fig. 3.5). Additionally, we showed
that gmppb mutants that appear “severe” exhibit a greater degree of muscle degeneration than
those that do not. A birefringence experiment that examined embryos on a day-by-day basis
found that while severe gmppb mutants experienced more muscle degeneration, mild gmppb
mutants with muscle degeneration experienced recovery (data not shown). Taken together,
these data raise the possibility mild and severe gmppb mutants possess differences in
regenerative capacity. While immunohistochemistry and fixing embryos at various stages can
provide initial insight into this question, longitudinal birefringence and confocal imaging of
gmppb mutants is a more ideal approach to address this. These rigorous techniques would also
allow us to image gmppb mutants earlier than 2 dpf while still accurately classifying their
phenotypic severity.
To address questions regarding regeneration in mild and severe gmppb mutants, we
must cross gmppb mutants with a transgenic line. We would cross gmppb mutants with
Tg(mylpfa:lyn-cyan, smych1:GFP, myog:H2B:RFP) transgenic fish (a kind gift from Dr. Jared
Talbot) that label fast-twitch muscle fibers (cyan), slow-twitch muscle fibers (green), and
myonuclei (red). Next, we would screen for heterozygous carriers that express these transgenes
of interest. Beginning at 24 hpf, wild-type and gmppb mutant transgenics would be live-imaged
via confocal microscopy daily. From 2 dpf to 7 dpf, these same fish would be imaged via
birefringence immediately before confocal imaging. Such rigorous live imaging of muscle fibers
and myonuclei would allow us to determine whether differences in muscle regeneration and/or
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degeneration drive phenotypic variation and plasticity in gmppb mutants (Fig. 4.1B). These
experiments would also allow us to examine other attributes of muscle development and
homeostasis over time.
4.5.3. Does early motor axon pathfinding influence phenotypic severity?
In addition to muscle phenotypes, gmppb mutants also have delayed motor axon
pathfinding and reduced fast-twitch fiber innervation (Fig. 3.4). Although levels of distributed
innervation did not significantly differ between gmppb embryos that appeared mild or severe, it
is still possible that motor axon pathfinding varies between mutants classified as mild or severe
via birefringence image analysis. A number of ECM molecules that participate in motor axon
pathfinding are glycosylated (Feldner et al., 2007; Guillon et al., 2016; Hilario et al., 2009;
Schneider and Granato, 2006). Therefore, levels of primary motor axon pathfinding early in
development is another potential mechanism underlying phenotypic variation in gmppb
mutants. To answer this question, we can identify gmppb mutants crossed with Tg(mylpfa:lyncyan, smych1:GFP, myog:H2B:RFP) transgenic fish that only carry Tg(mylpfa:lyn-cyan) and
establish a Tg(mylpfa:lyn-cyan);gmppb mutant line. Embryos from this line would be injected
with transgenic mnx1:mKate (Gribble et al., 2018) and gata2:GFP (Meng et al., 1997) constructs
in order to also study motor axon pathfinding in gmppb mutants. These embryos would be
imaged via confocal microscopy daily beginning at 24 hpf, and for birefringence daily beginning
at 48 hpf. These experiments would allow us to longitudinally image motoneurons in gmppb
mutants and determine if differences in motor axon pathfinding, neurodegeneration, or
compensatory innervation mechanisms drive phenotypic variation in gmppb mutants (Fig. 4.1C).
We are especially interested in determining if levels of motor axon pathfinding influence muscle
architecture or muscle degeneration and/or regeneration.
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4.5.4. Investigating differences in cell adhesion strength
Our results presented in Chapter 3, particularly regarding fiber detachment, suggest that
differences in cell-matrix adhesion may exist between mild and severe gmppb mutants. In
zebrafish, muscle fibers can detach either due to sarcolemmal damage or detachment from the
MTJ prior to sarcolemmal damage (Hall et al., 2007). A preliminary experiment that used Evan’s
Blue Dye (EBD) to examine this in gmppb mutants found that fibers primarily detach from the
MTJ prior to loss of sarcolemmal integrity (data not shown). This suggests that cell-ECM
adhesion is disrupted in gmppb mutants; thus, it would be useful to determine if gmppb
mutants exhibit variability in terms of cell adhesion strength.
Questions regarding this topic in gmppb mutants can be approached in multiple ways.
One straightforward approach involves using electrostimulation to test cell adhesion strength.
This technique has been previously used in zebrafish to induce muscle contraction and to test
muscle strength (Subramanian and Schilling, 2014) and can be employed to determine whether
severe gmppb mutants experience greater fiber loss than mild gmppb mutants when stimulated
(Fig. 4.1D). We plan to perform experiments where control, mild, and severe gmppb embryos
are imaged for birefringence at 2 dpf. Embryos will immediately receive two rounds of
electrostimulation followed by subsequent birefringence imaging, and we will determine
whether severe gmppb mutant embryos experience a greater reduction in birefringence after
two rounds of electrostimulation than mild gmppb mutant embryos. If this were the case, this
outcome would suggest that severe gmppb mutants have reduced cell adhesion and fiber
resiliency compared to mild gmppb mutants. Fixing and staining embryos for phalloidin and for
cell adhesion/MTJ markers such as laminin after electrostimulation should also be considered in
when performing these experiments.
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4.6. Concluding remarks
This dissertation highlights the importance of viewing dystroglycanopathies as individual
conditions. Specifically, our work suggests that this mindset is important in regard to distinct
dystroglycanopathy genes and the same dystroglycanopathy gene. The experiments described in
this chapter are designed to elucidate the mechanisms of disrupted neuromuscular
development, cell-matrix adhesion, and phenotypic variation in dystroglycanopathies. Research
regarding the tissue-specific requirements of Fkrp will determine where Fkrp is required for
neuromusculoskeletal development and homeostasis. Analysis of RNA-seq data examining mild
and severe gmppb mutant phenotypes, cell adhesion experiments, and longitudinal studies
involving both birefringence and confocal microscopy will yield valuable information regarding
the molecular and cellular mechanisms that contribute to phenotypic variation and plasticity in
the context of dystroglycanopathy. As mentioned, there are many additional approaches to
teasing apart these mechanisms. Studies that incorporate different perspectives and examine
these conditions at the molecular and cellular levels have the greatest potential to broaden our
understanding of dystroglycanopathies and provide insight for other basic researchers,
translational scientists, clinicians, and patients and their families.
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CHAPTER 5
MATERIALS AND METHODS
5.1. Zebrafish husbandry and lines
5.1.1. Zebrafish husbandry
All embryos were obtained from natural spawnings of adult zebrafish maintained on a
14 hour light/10 hour dark cycle at 28.5°C. Embryos were reared in 1X Embryo Rearing Medium
(ERM) with methylene blue and staged according to (Kimmel et al., 1995). The following strains
were utilized/generated: AB, Tg(fli1:EGFP) (Lawson and Weinstein, 2002), Tg(ef1α:xbp1δ-GFP)
(Li et al., 2015) (a kind gift from Dr. Shao Jun Du), Tg(hsp70l:pxn-EGFP) (Coffey et al., 2018),
Tg(hsp70l:fkrp-EGFP), and Tg(-503unc:fkrp-EGFP).
5.1.2. Construction of new transgenic lines
The Tg(hsp70l:fkrp-EGFP) and Tg(-503unc:fkrp-EGFP) lines were generated via the
gateway cloning system. A sequence surrounding the fkrp gene was amplified with NCBI-verified
primers was gated and inserted into the pDONR221 vector (Invitrogen). The heat shock gateway
222 5’ vector, GFP gateway 366 3’ vector, and the gateway 394 destination vector (Kwan et al.,
2007) were used along with the donor vector and LR clonase II for the Tg(hsp70l:fkrp-EGFP) line.
Components remained the same for the Tg(-503unc:fkrp-EGFP) line with the exception of the 503unc zebrafish muscle-specific promoter (Berger and Currie, 2013), which was used in place of
the heat shock gateway 222 5’ vector. Plasmids were injected at the single cell stage as
previously described (Goody et al., 2010).
5.1.3. Construction of gmppb mutants
The single guide RNA (sgRNA) targeting the gmppb sequence (NCBI gene ID: 445097)
was selected using CHOPCHOP (Montague et al., 2014). SgRNA synthesis was performed as
previously described (Gagnon et al., 2014) with the following modifications. Oligonucleotide
94

annealing reactions were doubled and incubated for 40-60 minutes at 12°C. The sgRNA
transcription reaction was doubled and synthesized using a MaxiScript Kit, and clean-up was
performed in 4 µl lithium chloride and 150 µl 100% ethanol. Cas9 mRNA was synthesized as
previously described (Gagnon et al., 2014). Gmppb sgRNA, Cas9, and a stop-cassette
oligonucleotide (Table 5.1) were injected into one-cell stage AB embryos. F0 embryos with
successful stop-cassette insertions were raised to adulthood and crossed to generate F1
embryos. F1 embryos were raised to adulthood and outcrossed with ABs to generate F2
embryos. All experiments described in Chapter 3 were performed using spawns of the F2
generation or later.

Table 5.1. Sequences used to construct gmppb mutants via CRISPR/Cas9 mutagenesis.
Sequences used to construct gmppb mutants with CRISPR/Cas9 mutagenesis technology. Note
the target site is not a synthesized nucleotide and that the protospacer adjacent motif (PAM)
sequence is underlined.
Nucleotide or Sequence
Name
GMPPB Target Site (not a
synthesized nucleotide)
GMPPB Gene-Specific
Oligonucleotide
GMPPB Stop-Cassette
Oligonucleotide
Left Homology Sequence
Right Homology Sequence

Sequence
GGACTCCAGCCTGAACACAGAGG
ATTTAGGTGACACTATAGGACTCCAGCCTGAACACAGGTTTTAGAG
CTAGAAATAGCAAG
ACCATCCAACGGTGCCTCTGGTCATGGCGTTTAAACCTTAATTAAGCT
GTTGTAGTGTTCAGGCTGGAGTCCGTC
ACCATCCAACGGTGCCTCTG
TGTTCAGGCTGGAGTCCGTC

5.2. Morpholino injections
Antisense MOs were obtained from Gene Tools, LLC, and hydrated at 65°C for 10
minutes with sterile water to generate 1 mM stocks. For fkrp morphant experiments, the
previously published fkrp MO2 (5’-CTTGTGGTTTTATGGCAGAAAGAGT-3’) (Kawahara et al., 2010)
was utilized and injected into the yolk of 1-2 cell stage embryos so that embryos received
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approximately 3.2 ng of MO. For dag1 morphant experiments, the previously published dag1
MO (dag1 MO1) (5’-CATGCCTGCTTTTATTTTCCCTCGC-3’ (Parsons et al., 2002) and an additional
slightly overlapping dag1 MO (dag1 MO2) (5’-CCCTCGCTCGTACAAAAGAGGACGT-3’) were coinjected into the yolk of 1-2 cell stage embryos so that embryos received approximately 12 ng of
each dag1 MO1 and dag1 MO2. Embryos utilized in experiments alongside NAD+ and EmergenC
treated embryos were placed in 60 mm Petri dishes with 25 embryos per dish in 10 mL 1X ERM.
5.3. NAD+ and EmergenC supplementation
Embryos receiving EmergenC treatment (Alacer Corp) were separated into 60 mm Petri
dishes with 25 embryos per dish in 10 mL 1X ERM-EmergenC solution. The NAD+ solution was
prepared as previously described (Goody et al., 2010) except in sterile water. The EmergenC
solution was diluted in 1X ERM so that the level of niacin in the solution was equal to 7.61 µM.
Supplementation began at 6 hpf or 24 hpf depending on the experiment and the solution was
changed every 24 hours until embryo fixation.
5.4. Expression of constructs with the heat shock promoter
To constitutively overexpress Fkrp, uninjected and injected Tg(hsp70l:fkrp-EGFP)
embryos were heat shocked at 38°C for 1.25-2 hours at the 15 somite stage. To overexpress
Paxillin, Tg(hsp70l:pxn-EGFP) were heat shocked at 38°C for 1.5 hours at 12 hpf, then for 1.5-2
hours daily until fixation. Heat-shocked fish were immediately transferred to 28°C.
5.5. Mobility assays
To assess mobility in fkrp morphants, touch response analysis was performed at 3
dpf. Embryos were placed in 1X ERM and stimulated at the posterior end with fishing wire. The
number of touches to evoke an escape response was recorded. For embryos that did not
respond after 50 touches, 50 was recorded as their touches to response. Mobility in gmppb
mutants was assessed as previously described (Goody et al., 2012).
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5.6. Immunohistochemistry
All embryos were fixed in 4% Paraformaldehyde (PFA) for 2-4 hours at roomtemperature, depending on the stage. After fixation, embryos received five rinses in PBS-0.1%
Tween 20. For all embryos not stained with alpha-Bungarotoxin or anti-znp-1, embryos were
permeabilized for 1.5 hours in PBS-2% Triton-X-100, followed by incubation in 1/20 phalloidin546 (Invitrogen) overnight at 4°C. Embryos were then subjected to five rinses for five minutes in
PBS-0.1% Tween 20, followed by an overnight incubation in antibody block (5%BSA, 1% DMSO,
1% Triton-X-100, 0.2% saponin in 1X PBS) for embryos receiving subsequent
immunohistochemistry treatments. Primary antibodies were added at a concentration of 1:50
(anti-laminin, anti-paxillin, anti-beta-dystroglycan) in antibody block and incubated for 2-8 hours
at room temperature followed by overnight at 4°C. All embryos were then treated with antibody
block for 8 hours at room temperature or overnight at 4°C, followed by an overnight incubation
in 1:200 secondary antibody (GAR488 and GAR633 for polyclonal; GAM488 and GAM633 for
monoclonal), either preceded or succeeded by a 2-6 hour incubation at room temperature,
depending on the antibody. Embryos were rinsed out of secondary antibody with PBS-0.1%
Tween 20 prior to deyolking, mounting, and imaging.
NMJ staining was performed as mentioned above with the following changes. After
rinsing embryos out of 4% PFA, embryos were permeabilized in 1 mg/ml collagenase in 1X PBS
for 1.25-1.5 hours. Embryos were stained with 1/500 α-Bungarotoxin-647 for 2-4 hours at room
temperature or overnight at 4°C. For co-staining, 1/20 phalloidin-546 was added to the alphaBungarotoxin solution in antibody block. Embryos were then rinsed as described above. Primary
SV2 antibody was added at a concentration of 1:50 in antibody block and embryos were
incubated in this solution for 2-8 hours at room temperature followed by 3 days at 4°C. Staining
then proceeded as described above.
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For anti-znp-1 staining, embryos were rinsed out of PFA as described above. Embryos
were then dehydrated and rehydrated with methanol (MeOH) with 5 minute incubations (10
minutes for 100% MeOH) in the following series: 0%, 33%, 66%, 100%, 66%, 33%, 0% MeOH.
Embryos were immediately blocked in antibody block for 2 hours at room temperature, and
then were incubated in primary anti-znp-1 antibody at a concentration of 1:50 in antibody block
overnight at 4°C. Staining then proceeded as described above.
5.7. Myofiber purification and staining
Individual myofibers from control and gmppb mutant zebrafish embryos were purified
at 48 hpf as previously described (Horstick et al., 2013). Purified myofibers were then fixed in 4%
PFA for fifteen minutes, rinsed three times for five minutes with PBS-0.1% Tween 20. Myofibers
were permeabilized for three minutes in PBS-2% Triton-X-100, subsequently rinsed once with
PBS-0.1% Tween 20, and stained with 1:40 phalloidin-546 in PBS-0.1% Tween 20 overnight at
4°C. Myofibers were rinsed the following morning three times for five minutes with PBS-0.1%
Tween 20, were blocked overnight in antibody block at 4°C, then stained for beta-dystroglycan
overnight at 4°C. Myofibers were rinsed three times for five minutes with PBS-0.1% Tween 20,
blocked for three hours at room temperature, and then incubated in secondary antibody
(GAM488) overnight at 4°C. Embryos were then rinsed five times for five minutes with PBS-0.1%
Tween 20.
5.8. Imaging
For live brightfield and birefringence imaging, embryos were anesthetized in Tricaine,
placed into a glass-bottomed dish, and imaged on a Leica screening microscope with camera
attachment. For birefringence images, a polarized light filter attachment was placed onto the
microscope. All live brightfield and birefringence images were taken at 2.5X and 3.2X. Fixed and
stained embryos were deyolked, mounted, and imaged in 80% glycerol as previously described
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(Goody et al., 2012). Fluorescent images of embryos were captured at 20X with a Zeiss Axio
Imager Z1 microscope with a Zeiss ApoTome attachment, at 20X with an Olympus Fluoview IX81 inverted microscope with FV1000 confocal system, or at 25X with a Leica DMi8 confocal
microscope. Images for Tg(ef1α:xbp1δ-GFP) were acquired at 10X on a Zeiss Axio Imager Z1
microscope with a Zeiss ApoTome attachment or at 5X on a Zeiss microscope with Vivatome
attachment. Exposure time was kept consistent between all embryo groups within an
experiment for Tg(ef1α:xbp1δ-GFP) experiments.
5.9. Statistical analyses
All statistical analyses were performed in GraphPad PRISM 8. Quantitative data were log
transformed before performing statistical comparisons. Statistical comparisons of quantitative
data were performed using an unpaired two-tailed t-test for comparisons of two groups and an
ordinary one-way ANOVA with Tukey’s ad-hoc analysis for comparisons of three or more groups.
Categorical MTJ staining intensity data were analyzed using Fisher’s Exact Test for two
categories and a Chi Square test for three or more categories.
5.10. Image analyses
5.10.1. Birefringence image analysis
Birefringence was quantified using FIJI as previously described (Berger et al., 2012) with
the following modifications. For each experiment, a polygon was drawn around the fish body of
a birefringence image between myotomes 6 and 26, and the area and mean gray value (MGV)
were measured. This was repeated three times for each embryo, and the values were averaged.
The average area and MGV for all controls were subsequently calculated. These values were
used to determine the percent area and percent MGV for all embryos. Mutants with a percent
area and a percent MGV at 85% or higher were classified as mild mutants.

99

5.10.2. Phenotypic classification
Embryos that received only phalloidin and/or NMJ staining (Fig. 3.3, 3.4) were
retroactively classified as “mild” or “severe,” as these experiments were performed prior to our
longitudinal studies. We initially planned to use gmppb mutants to study the relationship
between muscle degeneration, MTJs, and NMJs; however, we observed remarkable phenotypic
variation in the muscle of gmppb mutants in our confocal images. These observations were the
basis for the longitudinal studies we conducted. For embryos imaged via birefringence, the
percent area and MGV values described above were used to determine the phenotypic class of
gmppb mutant embryos. Mutants with a percent area and a percent MGV at 85% or higher we
classified as mild mutants. Embryos that did not meet these criteria were classified as severe
mutants.
5.10.3. Myotome scoring
Muscle fiber degeneration was quantified by counting the number of muscle segments
with degeneration per embryo and calculating the percent of myotomes with muscle
degeneration. For laminin and beta-DG staining analyses, images were blinded using a Perl script
and embryos were scored according to their relative staining intensity (Appendix A).
5.10.4. MTJ angles
Myotendinous junction angles were analyzed in FIJI (Schindelin et al., 2012; Schneider et
al., 2012) (Schindelin et al., 2012; Schneider et al., 2012) by using the angle tool.
5.10.5. Anisotropy analysis
For anisotropy analysis, a polygon was drawn in eight myotomes per image analyzed
using the polygonal lasso tool in Adobe Photoshop. The x,y coordinates of each polygon were
recorded. Masks were generated from the coordinates, and 2DWTMM analysis was performed
on each of these masks as previously described (Goody et al., 2010; Goody et al., 2012).
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5.10.6. Fluorescence intensity
For analysis of xbp1 transgenic embryos, fluorescence intensity was quantified using FIJI.
A polygon was drawn around the dorsal muscle above the notochord for all embryos in the
trunk region. The average pixel intensity (mean gray value) was calculated. The mean average
pixel intensity for all controls was calculated. These values were used to determine the percent
average pixel intensity for all embryos. Images for all xbp1 transgenic embryos were blinded
using a Perl script prior to analysis.
5.10.7. Intersegmental vessel and motoneuron lengths
Intersegmental vessel (ISV) lengths and primary motoneuron lengths were measured in
FIJI using the segmented line tool.
5.10.8. NMJ analysis
Confocal images were processed into maximum intensity projections of distributed and
myoseptal innervation using FIJI. Masks for the fish, horizontal myoseptum, and myoseptal
innervation were generated in FIJI and were subsequently imported into MATLAB (Mathworks)
for segmentation of the red (AChR) and green (SV2) fluorescence channels. Adaptive histogram
equalization (MATLAB “adapthisteq” function) was used to enhance the images, and a 1 pixel
radius Gaussian filter (MATLAB ‘imguassfilt’ function) was used to denoise the images. A
threshold of 30 was used on each channel to generate single masks of fluorescence images,
which were then combined with an or statement. Masks were skeletonized, and then cleaned
and despurred using the “bwmorph” command in MATLAB. This command was also used to
identify branchpoints. Muscle segments (half-myotomes) were defined using the masks for the
fish, horizontal myoseptum, and myoseptal innervation. Measurements of skeleton length and
branching frequency were then performed for each muscle segment (half-myotome) per
embryo.
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5.10.9. Myofiber analysis
For myofiber analysis, a polygon was drawn around each individual fiber in FIJI. The total
area, perimeter, and Feret’s diameter were measured for each individual fiber. The filament
index (a measure of how much an object’s shape deviates from circular) of the myofibers was
calculated as previously described (Snow et al., 2008b).
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APPENDIX A: CATEGORICAL SCORING OF MTJ STAINING INTENSITY

Figure A1. Scoring of relative MTJ staining intensity. (A-C) Anterior left, dorsal-side mounted
zebrafish embryos at 26 hpf stained for laminin-111 at the MTJ (purple). (A) Example of an
embryo with strong laminin staining intensity at the MTJ. (B) An embryo with weak laminin
staining intensity at the MTJ. (C) An embryo lacking laminin staining at the MTJ.
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APPENDIX B: PRELIMINARY RNA-SEQ DATA OF GMPPB MUTANTS
The following data are results of a collaboration with Dr. Benjamin King’s laboratory at
the University of Maine. The Henry laboratory sorted the wild-type and gmppb mutant embryos
prior to RNA extraction; the King laboratory performed the RNA extraction, sent the samples for
RNA sequencing, and compiled/analyzed the read data. RNA-seq was performed at the Hubbard
Center for Genome Studies at the University of New Hampshire. These data indicate the
presence of alternative splicing and differential gene expression in gmppb mutants. Analysis of a
second RNA-seq experiment with control, mild gmppb mutants, and severe gmppb mutants is
currently in progress (Kodey Silknitter and Dr. Benjamin King, personal communication).

Table B.1. RNA-seq reads of gmppb transcripts in gmppb mutants. Four distinct classes of
splice variants were detected in gmppb mutants. Protein products were predicted using the
Open Reading Frame (ORF) Viewer Tool. Data provided by Dr. Benjamin King (personal
communication).
Category of Read
Properly spliced (normal)
Unspliced
7 base pair insertion from intron
8 base pair cassette insertion and 8 base pair
insertion from intron
24 base pair cassette insertion and 8 base pair
insertion from intron
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Predicted Protein Product
Normal protein product
Currently Unknown
Frameshift with premature stop codon
at amino acid 59
Frameshift with premature stop codon
at amino acid 58
Frameshift with premature stop codon
at amino acid 47

Figure B.1. Examples of RNA-seq reads of gmppb transcripts. (A) Correctly spliced read. (B)
Mis-spliced read with 7 bp insertion from intron (red box). (C) Mis-spliced read with 8 bp
cassette insertion (gray box) and 8 bp insertion from intron (red box). (D) Mis-spliced read with
24 bp cassette insertion (gray and blue boxes) and 8 bp insertion from intron (red box). Exon 2
sequences are in green font, exon 3 sequences are in blue font. The last base pair of exon 2 and
first base pair of exon 3 are surrounded by a yellow box. Data provided by Kodey Silknitter and
Dr. Benjamin King (personal communication).
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